
@article{ ISI:000367291200002,
Author = {Exposito, Jose and Linares, Isabel and Castillo, Isabel and Martinez,
   Miguel and Vargas, Pilar and Herruzo, Ismael and Antonio Medina, Jose
   and Palacios, Amalia and Bayo, Eloisa and Peracaula, Francisco and Jaen,
   Javier and Antonio Sanchez, Jose and Jose Ortiz, Maria},
Title = {{Evaluation of the utilization of external radiotherapy in the treatment
   of localized prostate cancer in Andalusia, Spain}},
Journal = {{RADIATION ONCOLOGY}},
Year = {{2015}},
Volume = {{10}},
Month = {{DEC 30}},
Abstract = {{Background: Around 27,000 new cases of prostate cancer are diagnosed
   every year in Spain and 5400 die from this disease. Radiotherapy (RT),
   alone or combined, has proven to be effective as initial treatment in
   patients with localized disease. Our objective was to evaluate the use
   of external beam RT (EBRT) in our region, comparing the indication rate
   and irradiation rate and examining variability in its application among
   hospitals.
   Methods: We conducted a review of RT guidelines and indication studies
   for prostate cancer (\% expected irradiation). Data were gathered from
   all twelve public healthcare centers in Andalusia (Spain) on RT-treated
   prostate cancer patients during 2013 (\% actual irradiation) and from
   nine of the centers on RT discharge reports. Information was classified
   according to type of hospital, tumor risk category and RT treatment
   (technique, dosage, volume, toxicity).
   Results: The estimated RT rate was 67 \% (1289/1917), 43 \% were aged >
   70 years, 44.7 \% had ECOG performance status of 0); 44.7 \% had
   high-risk tumors; 57 \% underwent RT associated with hormone therapy; 70
   \% of patients receiving RT were treated with 3D planning (30 \% IGRT);
   and doses were 70-76 Gy in 70 \% of cases and > 76 Gy in 10.7 \%. Acute
   gastrointestinal and genitourinary toxicities were < grade 2 in 79 and
   89 \% of patients, respectively. An irradiation rate significantly below
   the mean for the study was found in four provinces. There was a
   significant difference among provinces in the distribution of risk
   groups.
   Conclusions: Underutilization of EBRT was estimated to be around 30 \%
   in prostate cancer patients, with an elevated variability in irradiation
   rates among hospitals related to differences in available technology and
   in the distribution of patients with different risk levels. These data
   should be a matter of concern to regional health managers, given the
   negative and measurable impact on the survival of patients.}},
Publisher = {{BIOMED CENTRAL LTD}},
Address = {{236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Linares, I (Reprint Author), Granada Gen Hosp, Radiotherapy \& Oncol Dept, Avda Fuerzas Armadas S-N, Granada 18014, Spain.
   Exposito, Jose; Linares, Isabel; Vargas, Pilar, Granada Gen Hosp, Radiotherapy \& Oncol Dept, Granada 18014, Spain.
   Castillo, Isabel, Granada Gen Hosp, Radiotherapy \& Oncol Dept, Granada 18012, Spain.
   Martinez, Miguel, Jaen Gen Hosp, Radiotherapy \& Oncol Dept, Jaen 23007, Spain.
   Herruzo, Ismael, Carlos Haya Univ Hosp, Radiotherapy \& Oncol Dept, Malaga 29010, Spain.
   Antonio Medina, Jose, Virgen de la Victoria Univ Hosp, Radiotherapy \& Oncol Dept, Malaga 29010, Spain.
   Palacios, Amalia, Reina Sofia Univ Hosp, Radiotherapy \& Oncol Dept, Cordoba 14004, Spain.
   Bayo, Eloisa, Juan Ramon Jimenez Hosp, Radiotherapy \& Oncol Dept, Huelva 21005, Spain.
   Peracaula, Francisco, Punta de Europa Algeciras Hosp, Radiotherapy \& Oncol Dept, Cadiz 11207, Spain.
   Jaen, Javier, Puerta del Mar Univ Hosp, Radiotherapy \& Oncol Dept, Cadiz 11009, Spain.
   Antonio Sanchez, Jose, Virgen Macarena Univ Hosp, Radiotherapy \& Oncol Dept, Seville 41071, Spain.
   Jose Ortiz, Maria, Virgen del Rocio Univ Hosp, Radiotherapy \& Oncol Dept, Seville 41013, Spain.}},
DOI = {{10.1186/s13014-015-0572-8}},
Article-Number = {{265}},
ISSN = {{1748-717X}},
Keywords = {{Prostate cancer; Radiotherapy; Variability; Use}},
Keywords-Plus = {{ESTRO-HERO SURVEY; BENCHMARKING APPROACH; GENERAL-POPULATION;
   LUNG-CANCER; COUNTRIES; BREAST; NEED; GUIDELINES; EQUIPMENT}},
Research-Areas = {{Oncology; Radiology, Nuclear Medicine \& Medical Imaging}},
Web-of-Science-Categories  = {{Oncology; Radiology, Nuclear Medicine \& Medical Imaging}},
Author-Email = {{ilg686@hotmail.com}},
ResearcherID-Numbers = {{Exposito Hernandez, Jose/L-9334-2014
   Virgen de la Victoria, Hospital/A-4296-2009}},
Cited-References = {{{[}Anonymous], 2009, SIT CANC ESP.
   Barton M., 2013, REV OPTIMAL RADIOTHE.
   Bentzen SM, 2005, RADIOTHER ONCOL, V75, P355, DOI 10.1016/j.radonc.2004.12.007.
   Bill-Axelson A, 2013, EUR UROL, V64, P920, DOI 10.1016/j.eururo.2013.02.025.
   Chamie K, 2015, JAMA ONCOL, DOI {[}10.1001/jamaoncol2014.192, DOI 10.1001/JAMAONCOL2014.192].
   Cozar JM, 2013, ACTAS UROL ESP, V37, P12, DOI 10.1016/j.acuro.2012.06.006.
   Delaney GP, 2015, CLIN ONCOL-UK, V27, P70, DOI 10.1016/j.clon.2014.10.005.
   Dunscombe P, 2014, RADIOTHER ONCOL, V112, P165, DOI 10.1016/j.radonc.2014.08.032.
   Exposito J., 2007, COMPREHENSIVE ANDALU.
   Exposito J, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-131.
   Fowler FJ, 1996, J CLIN ONCOL, V14, P2258, DOI 10.1200/JCO.1996.14.8.2258.
   Grau C, 2014, RADIOTHER ONCOL, V112, P155, DOI 10.1016/j.radonc.2014.08.029.
   Hegemann NS, 2014, RADIAT ONCOL, V9, DOI 10.1186/s13014-014-0275-6.
   Heidenreich A, 2013, GUIDELINES PROSTATE, P154.
   Kerba M, 2007, CLIN ONCOL-UK, V19, P481, DOI 10.1016/j.clon.2007.03.013.
   Kerba M, 2010, CLIN ONCOL-UK, V22, P801, DOI 10.1016/j.clon.2010.07.006.
   Kilsdonk MJ, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-596.
   Torrecilla JL, 2014, CLIN TRANSL ONCOL, V16, P447, DOI 10.1007/s12094-013-1121-2.
   Nag S, 1999, INT J RADIAT ONCOL, V44, P789, DOI 10.1016/S0360-3016(99)00069-3.
   Olasolo JJ, 2007, CLIN TRANSL ONCOL, V9, P789, DOI 10.1007/s12094-007-0141-1.
   Slotman BJ, 2013, RADIOTHER ONCOL, V106, P266, DOI 10.1016/j.radonc.2013.02.006.
   Sullivan R, 2011, LANCET ONCOL, V12, P933, DOI 10.1016/S1470-2045(11)70141-3.
   Tovar I, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-697.
   Tovar I, 2013, J THORAC ONCOL, V8, P62, DOI 10.1097/JTO.0b013e3182745640.
   Tyldesley S, 2011, INT J RADIAT ONCOL, V79, P1507, DOI 10.1016/j.ijrobp.2009.12.070.
   van Loon J, 2012, LANCET ONCOL, V13, pE169, DOI 10.1016/S1470-2045(11)70379-5.
   Zelefsky MJ, 2012, INT J RADIAT ONCOL, V84, P125, DOI 10.1016/j.ijrobp.2011.11.047.}},
Number-of-Cited-References = {{27}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{20}},
Journal-ISO = {{Radiat. Oncol.}},
Doc-Delivery-Number = {{CZ7PK}},
Unique-ID = {{ISI:000367291200002}},
OA = {{DOAJ Gold, Green Published}},
DA = {{2019-05-03}},
}

@article{ ISI:000366713500001,
Author = {Li Xiaoping and Zhang Xiaowei and Zheng Leizhen and Guo Weijian},
Title = {{Expression and significance of CD44 and p-AKT in pancreatic head cancer}},
Journal = {{WORLD JOURNAL OF SURGICAL ONCOLOGY}},
Year = {{2015}},
Volume = {{13}},
Month = {{DEC 15}},
Abstract = {{Background: CD44 and phosphorylated AKT (p-AKT) is a potentially
   interesting prognostic marker and therapeutic target in pancreatic
   cancer. The expression of CD44 and p-AKT has been reported to correlate
   with poor prognosis of pancreatic cancer in most literatures. The
   purpose of this study is to investigate the roles of CD44 and p-AKT in
   pancreatic head cancer and their correlation with the prognosis of
   pancreatic head cancer patients.
   Methods: Forty-eight pancreatic head cancer samples were collected
   dating from Jan. 2010 to Dec. 2012. Immunohistochemistry was applied to
   test the expression of CD44 and p-AKT in pancreatic head cancer. The
   clinical data of the patients were collected including their gender,
   age, the histology and location, lymph node metastasis, and so on. The
   correlation between the CD44 expression and the clinicopathological
   factors of patients with pancreatic head cancer was analyzed by the
   software SPSS 13.0.
   Results: The positive rates of CD44 and p-AKT expression in the samples
   were 64.6 and 29.2 \%, respectively. There was a significant difference
   between the CD44 expression and the pancreatic cancer' T staging, tumor
   node metastasis (TNM) staging, lymph node metastasis (P < 0.05). The Cox
   proportional hazard model showed that CD44 and lymph node metastasis
   were independent prognostic factors.
   Conclusions: CD44 was related to the distant metastasis and aggressive
   malignant behaviors of pancreatic head cancer.}},
Publisher = {{BIOMED CENTRAL LTD}},
Address = {{236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Zheng, LZ (Reprint Author), Shanghai Jiao Tong Univ, Dept Oncol, Xinhua Hosp, Sch Med, Shanghai 200092, Peoples R China.
   Li Xiaoping; Zheng Leizhen, Shanghai Jiao Tong Univ, Dept Oncol, Xinhua Hosp, Sch Med, Shanghai 200092, Peoples R China.
   Zhang Xiaowei; Guo Weijian, Fudan Univ, Canc Hosp, Dept Oncol, Shanghai 200032, Peoples R China.}},
DOI = {{10.1186/s12957-015-0746-8}},
Article-Number = {{334}},
ISSN = {{1477-7819}},
Keywords = {{CD44; p-AKT; Pancreatic head cancer; Metastasis; Prognosis}},
Keywords-Plus = {{CELL LUNG-CANCER; PROGNOSTIC VALUE; GASTRIC-CANCER; STEM-CELLS;
   METAANALYSIS; METASTASIS; RESISTANCE; SURVIVAL; DISEASE; ASSOCIATION}},
Research-Areas = {{Oncology; Surgery}},
Web-of-Science-Categories  = {{Oncology; Surgery}},
Author-Email = {{lxpmy@sohu.com
   gxmlxp@sohu.com}},
Cited-References = {{Adsay NV, 2012, SEMIN DIAGN PATHOL, V29, P127, DOI 10.1053/j.semdp.2012.08.010.
   Alexakis N, 2015, EJSO-EUR J SURG ONC, V41, P265, DOI 10.1016/j.ejso.2014.09.006.
   Chao YJ, 2014, BMC SURG, V14, DOI 10.1186/1471-2482-14-72.
   Chen K, 2014, ONCOL REP, V32, P755, DOI 10.3892/or.2014.3245.
   Chen YS, 2014, BIOMED PHARMACOTHER, V68, P693, DOI 10.1016/j.biopha.2014.08.001.
   Chou YE, 2014, BIOMED RES INT, V2014.
   Fitzgerald Timothy L., 2014, Advances in Biological Regulation, V56, P45, DOI 10.1016/j.jbior.2014.05.001.
   Follo Matilde Y, 2015, Adv Biol Regul, V57, P10, DOI 10.1016/j.jbior.2014.10.004.
   Hu H, 2014, BIOCHEM BIOPH RES CO, V452, P106, DOI 10.1016/j.bbrc.2014.08.059.
   Jiang W, 2015, MOL CANCER RES, V13, P9, DOI 10.1158/1541-7786.MCR-14-0076.
   Jung Y, 2015, ARCH PHARM RES, V38, P414, DOI 10.1007/s12272-015-0570-2.
   Lee SH, 2014, PANCREAS, V43, P380, DOI 10.1097/MPA.0000000000000097.
   Li L, 2014, GASTROENTEROLOGY, V146, P1108, DOI 10.1053/j.gastro.2013.12.035.
   Li XP, 2015, INT J CLIN EXP PATHO, V8, P6724.
   Li ZH, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-79.
   Liu J, 2010, ANN ACAD MED SINGAP, V39, P548.
   Luo Z, 2014, INT J CLIN EXP PATHO, V7, P3632.
   Maiolino S, 2015, NANOSCALE, V7, P5643, DOI 10.1039/c4nr06910b.
   McCubrey James A, 2015, Adv Biol Regul, V57, P75, DOI 10.1016/j.jbior.2014.09.016.
   Orian-Rousseau V, 2010, EUR J CANCER, V46, P1271, DOI 10.1016/j.ejca.2010.02.024.
   Rombouts SJE, 2015, BRIT J SURG, V102, P182, DOI 10.1002/bjs.9716.
   Tol JAMG, 2015, EJSO-EUR J SURG ONC, V41, P220, DOI 10.1016/j.ejso.2014.11.041.
   Turrini O, 2013, EJSO-EUR J SURG ONC, V39, P171, DOI 10.1016/j.ejso.2012.08.017.
   Wang L, 2014, TUMORI, V100, P321, DOI 10.1700/1578.17216.
   Wang W, 2014, INT J CLIN EXP MED, V7, P5059.
   Wood Natalie J, 2014, Nat Rev Gastroenterol Hepatol, V11, P73, DOI 10.1038/nrgastro.2014.1.
   Yoshida GJ, 2014, BIOCHEM BIOPH RES CO, V443, P622, DOI 10.1016/j.bbrc.2013.12.016.
   Zhan HX, 2015, CANCER LETT, V357, P429, DOI 10.1016/j.canlet.2014.12.004.
   Zhao S, 2014, ASIAN PAC J CANCER P, V15, P6761, DOI 10.7314/APJCP.2014.15.16.6761.}},
Number-of-Cited-References = {{29}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{6}},
Journal-ISO = {{World J. Surg. Oncol.}},
Doc-Delivery-Number = {{CY9FT}},
Unique-ID = {{ISI:000366713500001}},
OA = {{DOAJ Gold, Green Published}},
DA = {{2019-05-03}},
}

@article{ ISI:000366983500006,
Author = {Alese, O. B. and Kim, S. and Chen, Z. and Ramalingam, S. S. and
   Owonikoko, T. K. and El-Rayes, B. F.},
Title = {{Analysis of liver-directed therapies in US cancer patients}},
Journal = {{CURRENT ONCOLOGY}},
Year = {{2015}},
Volume = {{22}},
Number = {{6}},
Pages = {{E457-E461}},
Month = {{DEC}},
Abstract = {{Background The liver is a common site of primary and metastatic cancer.
   Liver-directed therapies are commonly used to treat cancer involving the
   liver. We report on the patterns, predictors, and outcomes of
   liver-directed therapies in hospitalized cancer patients in the United
   States.
   Methods Data were obtained from all U.S. states that contributed to the
   Nationwide Inpatient Sample maintained by the Agency for Healthcare
   Research and Quality between 2006 and 2010. Univariate and multivariate
   testing was used to identify factors significantly associated with
   patient outcome.
   Results For the 5-year period of interest, 12,540 patient discharges
   were identified. Mean age in the sample was 60 years. Primary liver
   lesions (n = 8840) made up 26.9\% of the sample; the remaining cases
   were metastases. Most procedures were performed in large (79\%) urban
   (98\%) hospitals and in patients with insurance (97.9\%). The most
   common intervention was partial hepatectomy (42.7\%), followed by open
   (9.9\%), percutaneous (7.2\%), and laparoscopic (5.04\%) ablation of
   liver lesions; embolization (9.8\%); and liver transplantation (2.64\%).
   The incidence of in-hospital mortality was very low (2.4\%), and the
   complication rate was 12.2\%. Complications such as acute liver
   necrosis, ascites, hepatic coma, hepatorenal syndrome, liver abscess,
   and high number of comorbid illnesses (>8) accounted for 60\% of the
   in-hospital mortality.
   Conclusions The low rate of morbidity and mortality associated with
   liver-directed therapies in hospitalized cancer patients supports the
   continuing utility of such procedures in the management of primary and
   metastatic liver cancer. The patterns of health disparities observed
   with respect to the use of liver-directed therapies are concerning.}},
Publisher = {{MULTIMED INC}},
Address = {{66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Alese, OB (Reprint Author), Emory Univ, Winship Canc Inst, 1365 Clifton Rd NE, Atlanta, GA 30322 USA.
   Alese, O. B.; Ramalingam, S. S.; Owonikoko, T. K.; El-Rayes, B. F., Emory Univ, Winship Canc Inst, Dept Hematol \& Oncol, Atlanta, GA 30322 USA.
   Kim, S., Cedars Sinai Med Ctr, Biostat \& Bioinformat Res Ctr, Los Angeles, CA 90048 USA.
   Chen, Z., Emory Univ, Dept Biostat, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.}},
DOI = {{10.3747/co.22.2819}},
ISSN = {{1198-0052}},
Keywords = {{Liver; therapies; predictors; outcomes; hospitalization}},
Keywords-Plus = {{HEPATOCELLULAR-CARCINOMA; TRANSARTERIAL CHEMOEMBOLIZATION; METASTASES;
   SURVIVAL}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Author-Email = {{oalese@emory.edu}},
Funding-Acknowledgement = {{U.S. National Institutes of Health {[}T32 CA160040-01A1]}},
Funding-Text = {{OBA is supported by U.S. National Institutes of Health grant T32
   CA160040-01A1 ( principal investigator: Dong M. Shin). TKO and BFE are
   Georgia Cancer Coalition Distinguished Cancer Scholars.}},
Cited-References = {{Abbott AM, 2013, ANN SURG ONCOL, V20, P139, DOI 10.1245/s10434-012-2515-z.
   ABBRUZZESE JL, 1995, J CLIN ONCOL, V13, P2094, DOI 10.1200/JCO.1995.13.8.2094.
   Aliberti C, 2006, ANTICANCER RES, V26, P3793.
   Ananthakrishnan Ashwin, 2006, Semin Intervent Radiol, V23, P47, DOI 10.1055/s-2006-939841.
   Barman PM, 2014, DIGEST DIS SCI, V59, P2821, DOI 10.1007/s10620-014-3247-7.
   Bester L, 2014, J MED IMAG RADIAT ON, V58, P341, DOI 10.1111/1754-9485.12163.
   Clark ME, 2014, J GASTROINTEST ONCOL, V5, P374, DOI 10.3978/j.issn.2078-6891.2014.064.
   Ho EY, 2014, HPB, V16, P758, DOI 10.1111/hpb.12214.
   Ko CJ, 2014, HEPATO-GASTROENTEROL, V61, P2295, DOI 10.5754/hge14739.
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254.
   Singla S, 2014, BIOMED RES INT, V2014.
   Stewart B., 2014, WORLD CANC REPORT 20.
   Vargas GM, 2014, J SURG RES, V191, P42, DOI 10.1016/j.jss.2014.05.070.
   Ward John W, 2013, Top Antivir Med, V21, P15.}},
Number-of-Cited-References = {{14}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Curr. Oncol.}},
Doc-Delivery-Number = {{CZ3DB}},
Unique-ID = {{ISI:000366983500006}},
OA = {{Bronze, Green Published}},
DA = {{2019-05-03}},
}

@article{ ISI:000368279300011,
Author = {Antonia Perez-Moreno, Maria and Cotrina-Luque, Jesus and
   Galvan-Banqueri, Mercedes and Flores-Moreno, Sandra and Javier
   Bautista-Paloma, Francisco and Angel Calleja-Hernandez, Miguel},
Title = {{Use of pemetrexed for non-small cell lung cancer in the Andalusian
   public health system}},
Journal = {{JOURNAL OF CHEMOTHERAPY}},
Year = {{2015}},
Volume = {{27}},
Number = {{6}},
Pages = {{371-377}},
Month = {{DEC}},
Abstract = {{The aim of this study is to determine the profile of the use of
   pemetrexed in metastatic or locally advanced NSCLC in Andalusia and its
   variation over 2 years (2010-2011). A prescription-indication
   observational retrospective multicenter study was conducted. Adult
   patients with locally advanced/metastatic NSCLC who received pemetrexed
   in any hospital in the Andalusian Public Health System during the first
   term of 2010 or the last term of 2011 were included. We collected
   patients' baseline characteristics, tumour histology and stage,
   pemetrexed indication and performance status at the start of treatment.
   In all, 107 and 170 patients (62 +/- 11 years old) from 17 hospitals
   were included in 2010 and 2011, respectively. The predominant histology
   was adenocarcinoma (85\%), 88\% of patients had stage IV tumours and
   52\% Eastern Cooperative Oncology Group stage (ECOG) 1.
   Pemetrexed indications in 2010 and 2011 were: First line combined with
   platinum (28.97-37.64\%); first line combined with platinum and
   maintenance with pemetrexed (24.30-28.82\%); second line monotherapy
   (12.15-7.65\%) and maintenance (2.15-7.05\%). Off-label use was detected
   in 22.43\% (2010) and 18.84\% (2011). In conclusion, pemetrexed combined
   with platinum is mainly used as first-line treatment in NSCLC patients
   with stage IV, adenocarcinoma histologic subtype and good performance
   status. Off-label use is high (especially in 2010). An adequate
   therapeutic positioning for pemetrexed based on effectiveness and safety
   analysis should be defined, so that NSCLC patients could be beneficiated
   with the most cost-effective chemotherapy treatment.}},
Publisher = {{TAYLOR \& FRANCIS LTD}},
Address = {{2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Perez-Moreno, MA (Reprint Author), Hosp Univ Virgen del Rocio, Dept Pharm, Ave Manuel Siurot S-N, Seville 41013, Spain.
   Antonia Perez-Moreno, Maria; Cotrina-Luque, Jesus; Galvan-Banqueri, Mercedes; Flores-Moreno, Sandra; Javier Bautista-Paloma, Francisco, Hosp Univ Virgen del Rocio, Dept Pharm, Seville 41013, Spain.
   Angel Calleja-Hernandez, Miguel, Hosp Univ Virgen de las Nieves, Dept Pharm, Granada, Spain.}},
DOI = {{10.1179/1973947815Y.0000000024}},
ISSN = {{1120-009X}},
EISSN = {{1973-9478}},
Keywords = {{Pemetrexed; Non-small-cell lung cancer; Drug utilisation study;
   Utilisation evaluation}},
Keywords-Plus = {{PHASE-III; 1ST-LINE TREATMENT; CISPLATIN; PLUS}},
Research-Areas = {{Oncology; Infectious Diseases; Pathology; Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Oncology; Infectious Diseases; Pathology; Pharmacology \& Pharmacy}},
Author-Email = {{mary@gmail.com}},
ResearcherID-Numbers = {{Mercedes, Galvan Banqueri/J-2650-2017}},
ORCID-Numbers = {{Mercedes, Galvan Banqueri/0000-0003-3553-2341}},
Funding-Acknowledgement = {{Health Department of the Spanish Government. (Investigacion Clinica
   Independiente. Ministerio de Sanidad y Politica Social)}},
Funding-Text = {{This study was supported by the Health Department of the Spanish
   Government. (Investigacion Clinica Independiente. Ministerio de Sanidad
   y Politica Social).}},
Cited-References = {{Alvarez Luna F., 2004, SEGUIMIENTO FARMACOT, V2, P129.
   American Cancer Society, 2001, GUID LUNG CANC SCREE.
   {[}Anonymous], 2013, PEMETREXED PRODUCT I.
   Bai JL, 2009, J TOXICOL ENV HEAL A, V72, P677, DOI 10.1080/15287390902840930.
   Brown T, 2013, HEALTH TECHNOL ASSES, V17, P1, DOI 10.3310/hta17060.
   Ciuleanu T, 2009, LANCET, V374, P1432, DOI 10.1016/S0140-6736(09)61497-5.
   DiPiro JT, 2011, PHARMACOTHERAPY PATH, V132, P2157.
   Fleeman N, 2010, HEALTH TECHNOL ASSES, V14, P47, DOI {[}10.3310/hta14Suppl1/07, 10.3310/hta14suppl1/07].
   Greenhalgh J, 2010, HEALTH TECHNOL ASSES, V14, P33, DOI 10.3310/hta14suppl2/05.
   Gridelli C, 2010, LUNG CANCER, V68, P319, DOI 10.1016/j.lungcan.2009.11.018.
   Hanna N, 2004, J CLIN ONCOL, V22, P1589, DOI 10.1200/JCO.2004.08.163.
   Hong Junshik, 2010, Korean Journal of Internal Medicine, V25, P294, DOI 10.3904/kjim.2010.25.3.294.
   National Comprehensive Cancer Network, 2013, NCCN CLIN PRACT GUID.
   Non squamous - NSCLC guide, 2010, ANDALUSIAN HOSP PHAR.
   NSCLC Spanish Society of Medical Oncology Guide, 2013, NSCLC SPANISH SOC ME.
   Paz-Ares LG, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-85.
   Picaza E, 2008, ATEN FARM, V10, P73.
   Santos-Ramos B, 2013, INT J CLIN PHARM-NET, V35, P550, DOI 10.1007/s11096-013-9791-y.
   Scagliotti GV, 2008, J CLIN ONCOL, V26, P3543, DOI 10.1200/JCO.2007.15.0375.
   Villanueva-Herraiz S, 2010, Farm Hosp, V34, P194, DOI 10.1016/j.farma.2009.12.010.}},
Number-of-Cited-References = {{20}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{J. Chemother.}},
Doc-Delivery-Number = {{DB1OY}},
Unique-ID = {{ISI:000368279300011}},
DA = {{2019-05-03}},
}

@article{ ISI:000217570600008,
Author = {Arbea, Leire and Aristu, Javier},
Title = {{The Role of Intensity-Modulated Radiotherapy to Optimize Outcomes in
   Locally Advanced Rectal Cancer}},
Journal = {{CURRENT COLORECTAL CANCER REPORTS}},
Year = {{2015}},
Volume = {{11}},
Number = {{6}},
Pages = {{345-351}},
Month = {{DEC}},
Abstract = {{Intensity-modulated radiation therapy (IMRT) as neoadjuvant treatment of
   locally advanced rectal cancer ( LARC) patients has been explored by
   some authors since 2006. Dosimetrical analyses and clinical outcomes
   have been published in recent years. Although there are encouraging
   dosimetrical results, there are no solid clinical data supporting the
   routine use of IMRT for preoperative treatment of LARC patients. In this
   article, we analyze the published dosimetrical and clinical data and
   current evidence for the use of IMRT in LARC patients. We hypothesize
   the role of IMRT to treat rectal cancer patients in the current
   technological age. The small bowel dose reduction that could lead to a
   reduction in GI toxicity and encourage higher rates of compliance, the
   potential dose escalation to the target volume, and the integration with
   higher doses of chemotherapy and its potential implications to optimize
   clinical outcomes in terms of toxicity and efficacy are discussed.}},
Publisher = {{SPRINGER}},
Address = {{233 SPRING ST, NEW YORK, NY 10013 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Arbea, L (Reprint Author), Univ Navarra, Clin Univ Navarra, Dept Oncol, Avda Pio 12 S-N, Pamplona, Navarre, Spain.
   Arbea, Leire; Aristu, Javier, Univ Navarra, Clin Univ Navarra, Dept Oncol, Avda Pio 12 S-N, Pamplona, Navarre, Spain.}},
DOI = {{10.1007/s11888-015-0289-y}},
ISSN = {{1556-3790}},
EISSN = {{1556-3804}},
Keywords = {{Locally advanced rectal cancer; Intensity-modulated radiation therapy;
   Gastrointestinal toxicity; Capecitabine; Oxaliplatin}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Author-Email = {{larbea@unav.es}},
ResearcherID-Numbers = {{Aristu, Javier/D-7594-2019}},
ORCID-Numbers = {{Aristu, Javier/0000-0002-0382-2363}},
Cited-References = {{Arbea L, 2012, INT J RADIAT ONCOL, V83, P587, DOI 10.1016/j.ijrobp.2011.06.2008.
   Arbea L, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-17.
   Aschele C, 2011, J CLIN ONCOL, V29, P2773, DOI 10.1200/JCO.2010.34.4911.
   Baglan KL, 2002, INT J RADIAT ONCOL, V52, P176, DOI 10.1016/S0360-3016(01)01820-X.
   Ballonoff A, 2008, AM J CLIN ONCOL-CANC, V31, P264, DOI 10.1097/COC.0b013e318161dbd3.
   Burbach JP, 2015, TRIALS, V16.
   Callister MD, 2006, INT J RADIAT ONCOL, V66, pS290, DOI 10.1016/j.ijrobp.2006.07.547.
   Eisbruch A, 2002, SEMIN RADIAT ONCOL, V12, P197, DOI 10.1053/srao.2002.32430.
   Engels B, 2014, RADIOTHER ONCOL, V110, P155, DOI 10.1016/j.radonc.2013.10.026.
   Engels B, 2012, INT J RADIAT ONCOL, V83, P142, DOI 10.1016/j.ijrobp.2011.05.068.
   Engels B, 2009, INT J RADIAT ONCOL, V74, P1476, DOI 10.1016/j.ijrobp.2008.10.017.
   Galvin JM, 2004, INT J RADIAT ONCOL, V58, P1616, DOI 10.1016/j.ijrobp.2003.12.008.
   Garofalo M, 2011, INT J RADIAT ONCOL, V81, pS3, DOI 10.1016/j.ijrobp.2011.06.008.
   Gerard JP, 2012, J CLIN ONCOL, V30, P4558, DOI 10.1200/JCO.2012.42.8771.
   Gerard JP, 2010, J CLIN ONCOL, V28, P1638, DOI 10.1200/JCO.2009.25.8376.
   Gerard JP, 2004, J CLIN ONCOL, V22, P2404, DOI 10.1200/JCO.2004.08.170.
   Glynne-Jones R, 2014, ANN ONCOL, V25, P1356, DOI 10.1093/annonc/mdu147.
   Guillem JG, 2005, ANN SURG, V241, P829, DOI 10.1097/01.sla.0000161980.46459.96.
   Hall EJ, 2003, INT J RADIAT ONCOL, V56, P83, DOI 10.1016/S0360-3016(03)00073-7.
   Hernando-Requejo O, 2014, STRAHLENTHER ONKOL, V190, P515, DOI 10.1007/s00066-014-0650-0.
   Kim DY, 2006, DIS COLON RECTUM, V49, P1684, DOI 10.1007/s10350-006-0678-z.
   Lee JH, 2012, INT J RADIAT ONCOL, V84, P955, DOI 10.1016/j.ijrobp.2012.01.045.
   McDonald MW, 2008, INT J RADIAT ONCOL, V72, P1031, DOI 10.1016/j.ijrobp.2008.02.053.
   Mok H, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-63.
   Myerson RJ, 2009, INT J RADIAT ONCOL, V74, P824, DOI 10.1016/j.ijrobp.2008.08.070.
   Nijkamp J, 2012, RADIOTHER ONCOL, V103, P353, DOI 10.1016/j.radonc.2012.02.013.
   Rodel C, 2005, J CLIN ONCOL, V23, P8688, DOI 10.1200/JCO.2005.02.1329.
   Rodel C, 2012, LANCET ONCOL, V13, P679, DOI 10.1016/S1470-2045(12)70187-0.
   Rodel C, 2012, CURR OPIN ONCOL, V24, P441, DOI 10.1097/CCO.0b013e328352ea02.
   Sauer R, 2003, Colorectal Dis, V5, P406.
   Sauer R, 2012, J CLIN ONCOL, V30, P1926, DOI 10.1200/JCO.2011.40.1836.
   Sebag-Montefiore D, 2009, RADIOTHER ONCOL, V92, P145, DOI 10.1016/j.radonc.2009.06.026.
   Suwinski R, 1998, INT J RADIAT ONCOL, V42, P943, DOI 10.1016/S0360-3016(98)00343-5.
   Tho LM, 2006, INT J RADIAT ONCOL, V66, P505, DOI 10.1016/j.ijrobp.2006.05.005.
   Urbano MTG, 2006, INT J RADIAT ONCOL, V65, P907, DOI 10.1016/j.ijrobp.2005.12.056.
   Valentini V, 2002, INT J RADIAT ONCOL, V53, P664, DOI 10.1016/S0360-3016(02)02764-5.
   Yeo SG, 2013, INT J RADIAT ONCOL, V86, P34, DOI 10.1016/j.ijrobp.2012.11.018.
   Zelefsky MJ, 2006, J UROLOGY, V176, P1415, DOI 10.1016/j.juro.2006.06.002.
   Zhu J, 2014, RADIAT ONCOL, V9.}},
Number-of-Cited-References = {{39}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Curr. Colorectal Cancer Rep.}},
Doc-Delivery-Number = {{V2G9R}},
Unique-ID = {{ISI:000217570600008}},
DA = {{2019-05-03}},
}

@article{ ISI:000219361100007,
Author = {Azim, Hamdy A. and Azim, Jr., Hatem A.},
Title = {{Potential Therapeutic Targets in Triple Negative Breast Cancer}},
Journal = {{CURRENT BREAST CANCER REPORTS}},
Year = {{2015}},
Volume = {{7}},
Number = {{4}},
Pages = {{215-223}},
Month = {{DEC}},
Abstract = {{Triple negative breast cancers (TNBC) are often described as
   biologically aggressive tumors, with poorer survival compared to other
   breast cancer subtypes. The fact that TNBC lacks an obvious target like
   estrogen receptor and HER2 represents a major challenge in the
   management of these patients. Genomic analyses have revealed that TNBC
   comprises a diverse group of cancers, which have distinct molecular
   profiles and different prognosis. These studies also highlighted
   molecular aberrations that could serve as potential treatment targets.
   On the other hand, a high percentage of TNBCs express some important
   surface receptors that have been already exploited in the development of
   promising targeted therapies, which are currently tested in clinical
   trials. In this review, we will provide an overview on the molecular
   diversity of TNBC with special emphasis on the evolving role of some
   potential biomarkers that may be utilized in the near future.}},
Publisher = {{SPRINGER}},
Address = {{233 SPRING ST, NEW YORK, NY 10013 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Azim, HA (Reprint Author), Cairo Univ, Fac Med, Dept Clin Oncol, 55 Abdel Monem Riad St, Cairo, Egypt.
   Azim, Hamdy A., Cairo Univ, Fac Med, Dept Clin Oncol, 55 Abdel Monem Riad St, Cairo, Egypt.
   Azim, Hatem A., Jr., BREAST Data Ctr, Inst Jules Bordet, Dept Med, Brussels, Belgium.}},
DOI = {{10.1007/s12609-015-0192-1}},
ISSN = {{1943-4588}},
EISSN = {{1943-4596}},
Keywords = {{Triple negative breast cancer; Biomarkers; Therapeutic targets; BRCA;
   Androgen receptor; LHRH; Breast cancer; Breast cancer biomarkers}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Author-Email = {{azimonc@cairocure.com
   hatem.azim@bordet.be}},
Cited-References = {{Abkevich V, 2012, BRIT J CANCER, V107, P1776, DOI 10.1038/bjc.2012.451.
   Anders CK, 2010, CLIN CANCER RES, V16, P4702, DOI 10.1158/1078-0432.CCR-10-0939.
   Andre F, 2012, ANN ONCOL, V23, P46, DOI 10.1093/annonc/mds195.
   BAUMANN KH, 1993, BREAST CANCER RES TR, V25, P37, DOI 10.1007/BF00662399.
   Beck C, 2014, EXP CELL RES, V329, P18, DOI 10.1016/j.yexcr.2014.07.003.
   Bendell J, 2014, J CLIN ONCOL, V32, P3619, DOI 10.1200/JCO.2013.52.5683.
   Brahmer J, 2015, N ENGL J MED.
   Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443.
   Buchholz S, 2012, HORM MOL BIOL CLIN I, V9, P87, DOI 10.1515/hmbci-2011-0002.
   Buchholz S, 2009, INT J ONCOL, V35, P789, DOI 10.3892/ijo\_00000391.
   Burstein MD, 2015, CLIN CANCER RES, V21, P1688, DOI 10.1158/1078-0432.CCR-14-0432.
   Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8.
   Criscitiello C, 2012, ANN ONCOL          S, V23, P3.
   Denkert C, 2010, J CLIN ONCOL, V28, P105, DOI 10.1200/JCO.2009.23.7370.
   Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045.
   Emens L. A. B, 2014, SAN ANT BREAST CANC.
   Emons G, 2014, INT J GYNECOL CANCER, V24, P260, DOI 10.1097/IGC.0000000000000044.
   Engel J, 2012, EXPERT OPIN INV DRUG, V21, P891, DOI 10.1517/13543784.2012.685128.
   Engel JB, 2015, ONCOTARGET, V6, P1898, DOI 10.18632/oncotarget.3271.
   Fadoukhair Z, 2015, ONCOGENE.
   Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445.
   Fong PC, 2010, J CLIN ONCOL, V28, P2512, DOI 10.1200/JCO.2009.26.9589.
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212.
   Gingras I, 2015, CLIN ADV HEMATOL ONC, V13, P1.
   Gonzalez LO, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-149.
   Guan X, 2015, ANTICANCER DRUGS.
   Gucalp A, 2013, CLIN CANCER RES, V19, P5505, DOI 10.1158/1078-0432.CCR-12-3327.
   Helleday T, 2008, NAT REV CANCER, V8, P193, DOI 10.1038/nrc2342.
   Isakoff SJ, 2015, J CLIN ONCOL, V33, P1902, DOI 10.1200/JCO.2014.57.6660.
   KAKAR SS, 1994, MOL CELL ENDOCRINOL, V106, P145, DOI 10.1016/0303-7207(94)90196-1.
   Kaufman B, 2015, J CLIN ONCOL, V33, P244, DOI 10.1200/JCO.2014.56.2728.
   Kim ES, 2011, CANCER DISCOV, V1, P44, DOI 10.1158/2159-8274.CD-10-0010.
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412.
   Kwok CW, 2014, TARGET ONCOL.
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014.
   Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147.
   Loi S, 2014, ANN ONCOL, V25, P1544, DOI 10.1093/annonc/mdu112.
   Loi S, 2013, J CLIN ONCOL, V31, P860, DOI 10.1200/JCO.2011.41.0902.
   Maric G, 2013, ONCOTARGETS THER, V6, P839, DOI 10.2147/OTT.S44906.
   Masuda H, 2013, CLIN CANCER RES, V19, P5533, DOI 10.1158/1078-0432.CCR-13-0799.
   Metzger O, 2013, J CLIN ONCOL, V31, P3083, DOI 10.1200/JCO.2012.46.1574.
   Metzger O, 2012, J CLIN ONCOL, V30, P1879, DOI 10.1200/JCO.2011.38.2010.
   Mohammed ZMA, 2012, BRIT J CANCER, V107, P864, DOI 10.1038/bjc.2012.347.
   Moore HCF, 2015, NEW ENGL J MED, V372, P923, DOI 10.1056/NEJMoa1413204.
   Nanda R., 2014, SAN ANT BREAST CANC.
   Niemeier LA, 2010, MODERN PATHOL, V23, P205, DOI 10.1038/modpathol.2009.159.
   O'Shaughnessy J, 2014, J CLIN ONCOL, V32, P3840, DOI 10.1200/JCO.2014.55.2984.
   O'Shaughnessy J, 2011, NEW ENGL J MED, V364, P205, DOI 10.1056/NEJMoa1011418.
   Ono M, 2012, BREAST CANCER RES TR, V132, P793, DOI 10.1007/s10549-011-1554-7.
   Park S, 2010, ANN ONCOL, V21, P488, DOI 10.1093/annonc/mdp510.
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093.
   Rose AAN, 2007, MOL CANCER RES, V5, P1001, DOI 10.1158/1541-7786.MCR-07-0119.
   Rose AAN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012093.
   Rose AAN, 2010, CLIN CANCER RES, V16, P2147, DOI 10.1158/1078-0432.CCR-09-1611.
   Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450.
   Seitz S, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-847.
   Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498.
   Sonnenblick A, 2015, NAT REV CLIN ONCOL, V12, P27, DOI 10.1038/nrclinonc.2014.163.
   Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100.
   Telli ML, 2015, J CLIN ONCOL, V33, P1895, DOI 10.1200/JCO.2014.57.0085.
   Traina TA, 2015, ASCO M, V33, P1003.
   Tse KF, 2006, CLIN CANCER RES, V12, P1373, DOI 10.1158/1078-0432.CCR-05-2018.
   Tsimberidou AM, 2012, CLIN CANCER RES, V18, P6373, DOI 10.1158/1078-0432.CCR-12-1627.
   Turner N, 2004, NAT REV CANCER, V4, P814, DOI {[}10.1038/nrc1457, 10.1038/nrc1452].
   Turner NC, 2013, CLIN CANCER RES, V19, P6380, DOI 10.1158/1078-0432.CCR-13-0915.
   Tutt A, 2014, P SAN ANT BREAST CAN.
   Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6.
   Vera-Badillo FE, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt319.
   Von Minckwitz G, 2014, J CLIN ONCOL, V32.
   von Minckwitz G, 2012, J CLIN ONCOL, V30, P1796, DOI 10.1200/JCO.2011.38.8595.
   VONMINCKWITZ G, 2015, J CLIN ONCOL S, V33.
   Watkins JA, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3670.
   Yamaguchi R, 2012, HUM PATHOL, V43, P1688, DOI 10.1016/j.humpath.2011.12.013.
   Yardley DA, 2015, J CLIN ONCOL, V33, P1609, DOI 10.1200/JCO.2014.56.2959.
   Yu Q, 2011, ANN ONCOL, V22, P1288, DOI 10.1093/annonc/mdq586.
   Zagouri F, 2015, BREAST, V24, P513, DOI 10.1016/j.breast.2015.02.031.}},
Number-of-Cited-References = {{76}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Curr. Breast Cancer Rep}},
Doc-Delivery-Number = {{V4X8I}},
Unique-ID = {{ISI:000219361100007}},
DA = {{2019-05-03}},
}

@article{ ISI:000367447400087,
Author = {Bacalbasa, Nicolae and Balescu, Irina and Dima, Simona and Popescu,
   Irinel},
Title = {{The Role of Re-resection for Breast Cancer Liver Metastases-a Single
   Center Experience}},
Journal = {{ANTICANCER RESEARCH}},
Year = {{2015}},
Volume = {{35}},
Number = {{12}},
Pages = {{6877-6880}},
Month = {{DEC}},
Abstract = {{The aim of the present study was to evaluate the effectiveness and
   safety of hepatic re-resection for breast cancer liver metastases.
   Patients and Methods : Between January 2004 and December 2014 seven
   patients were submitted to liver re-resection for breast cancer liver
   metastases at our Center. The main inclusion criteria were presence of
   isolated liver metastases and absence of systemic recurrent disease
   Results: The median age at the time of breast surgery was 51 years
   (range=39-69 years). The first liver resection was performed after a
   median period of 34.7 months and consisted of minor hepatectomies in six
   and major hepatectomy in one patient. The second liver resection was
   performed after a median interval of 22 months from the first liver
   resection and consisted of major resection in one case and minor
   resection in the other six cases. Postoperative complications occurred
   in a single case after the first liver surgery and in two cases after
   the second hepatic resection, all cases being successfully managed
   conservatively. Overall postoperative mortality was 0. The median
   overall survival after the second liver resection was 28 months.
   Conclusion: Re-resection for breast cancer liver metastases can be
   safely performed and may bring survival benefit.}},
Publisher = {{INT INST ANTICANCER RESEARCH}},
Address = {{EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Bacalbasa, N (Reprint Author), Dimitrie Racovita St 2, Bucharest, Romania.
   Bacalbasa, Nicolae; Popescu, Irinel, Carol Davila Univ Med \& Pharm, Dept Obstet \& Gynecol, Bucharest, Romania.
   Balescu, Irina, Ponderas Hosp, Dept Gen Surg, Bucharest, Romania.
   Dima, Simona; Popescu, Irinel, Fundeni Clin Inst, Dan Setlacec Ctr Gastrointestinal Dis \& Liver Tr, Bucharest, Romania.}},
ISSN = {{0250-7005}},
EISSN = {{1791-7530}},
Keywords = {{Breast cancer liver metastases; re-resection; survival}},
Keywords-Plus = {{PROGNOSTIC-FACTORS; HEPATIC RESECTION; NEUROENDOCRINE METASTASES;
   SURGICAL-TREATMENT; PROLONG SURVIVAL; 1ST RECURRENCE; HEPATECTOMY;
   OUTCOMES}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Author-Email = {{nicolae\_bacalbasa@yahoo.ro}},
ResearcherID-Numbers = {{Bacalbasa, Nicolae/A-4222-2017
   Dima, Simona Olimpia/B-8822-2017
   Clinical Institute, Fundeni/K-5773-2018
   POPESCU, IRINEL/B-3048-2008}},
ORCID-Numbers = {{Bacalbasa, Nicolae/0000-0001-8465-5079
   }},
Funding-Acknowledgement = {{European Social Fund;  {[}POSDRU/ 159/1.5/S/135760]}},
Funding-Text = {{This study was co-financed from the European Social Fund, through POSDRU
   2007-2013, Prioritary axis no. 1, Education and formation supporting
   economical development and aknowledgment based society development-
   major domain of intervention 1.5 ``Doctoral and post-doctoral programs
   supporting research{''} CERO-carrier profile: - Romanian researcher.
   Financial contract: POSDRU/ 159/1.5/S/135760}},
Cited-References = {{Abdalla EK, 2004, ANN SURG, V239, P818, DOI 10.1097/01.sla.0000128305.90650.71.
   Adam R, 2006, ANN SURG, V244, P897, DOI 10.1097/01.sla.0000246847.02058.1b.
   Altekruse CL, 2010, SEER CANC STAT REV.
   Bacalbasa N, 2014, ANTICANCER RES, V34, P5563.
   Belda T, 2010, CIR ESPAN, V88, P167, DOI 10.1016/j.ciresp.2010.05.005.
   Caralt M, 2008, ANN SURG ONCOL, V15, P2804, DOI 10.1245/s10434-008-0072-2.
   Chamberlain RS, 2000, J AM COLL SURGEONS, V190, P432, DOI 10.1016/S1072-7515(00)00222-2.
   Chen H, 1998, J AM COLL SURGEONS, V187, P88, DOI 10.1016/S1072-7515(98)00099-4.
   Chua TC, 2011, EUR J CANCER, V47, P2282, DOI 10.1016/j.ejca.2011.06.024.
   CLARK GM, 1987, J CLIN ONCOL, V5, P55, DOI 10.1200/JCO.1987.5.1.55.
   Elias D, 2003, AM J SURG, V185, P158, DOI 10.1016/S0002-9610(02)01204-7.
   Fernandez FG, 2004, ANN SURG, V240, P438, DOI 10.1097/01.sla.0000138076.72547.b1.
   Giordano SH, 2004, CANCER, V100, P44, DOI 10.1002/cncr.11859.
   Groeschl RT, 2012, J AM COLL SURGEONS, V214, P769, DOI 10.1016/j.jamcollsurg.2011.12.048.
   HOE AL, 1991, J ROY SOC MED, V84, P714.
   Hoffmann K, 2010, ANN SURG ONCOL, V17, P1546, DOI 10.1245/s10434-010-0931-5.
   Insa A, 1999, BREAST CANCER RES TR, V56, P67, DOI 10.1023/A:1006285726561.
   Kornasiewicz Oskar, 2015, Pol Przegl Chir, V86, P544, DOI 10.2478/pjs-2014-0097.
   Lubrano J, 2008, SURG TODAY, V38, P293, DOI 10.1007/s00595-007-3617-2.
   Mayo SC, 2011, ANN SURG ONCOL, V18, pS220, DOI 10.1245/s10434-010-1343-2.
   Sarmiento JM, 2003, J AM COLL SURGEONS, V197, P29, DOI 10.1016/S1072-7515(03)00230-8.
   van Walsum GAM, 2012, EJSO-EUR J SURG ONC, V38, P910, DOI 10.1016/j.ejso.2012.04.015.
   Vlastos G, 2004, ANN SURG ONCOL, V11, P869, DOI 10.1245/ASO.2004.01.007.
   ZINSER JW, 1987, J CLIN ONCOL, V5, P773, DOI 10.1200/JCO.1987.5.5.773.}},
Number-of-Cited-References = {{24}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{11}},
Journal-ISO = {{Anticancer Res.}},
Doc-Delivery-Number = {{CZ9WH}},
Unique-ID = {{ISI:000367447400087}},
DA = {{2019-05-03}},
}

@article{ ISI:000368051000007,
Author = {Bellier, Thibault and Vallard, Alexis and Espenel, Sophie and
   Langrand-Escure, Julien and Ben Mrad, Majed and Vedrine, Lionel and
   Magne, Nicolas and Chargari, Cyrus},
Title = {{Role of general practitioners in cancer screening: A survey in the
   French armed forces}},
Journal = {{BULLETIN DU CANCER}},
Year = {{2015}},
Volume = {{102}},
Number = {{12}},
Pages = {{993-1001}},
Month = {{DEC}},
Abstract = {{Introduction > The French Military Health Service organizes medical
   survey of 340,000 military men. The aim of the present study was to
   evaluate the practices of solid cancer screening of general
   practitioners in military medical units and to compare the results with
   the recommendations of the French National Institute of Cancer.
   Methods > We conducted a prospective, observational study among general
   practitioners in Army Medical Unit by sending them a self-assessment
   questionnaire. Physicians should report on their practices for screening
   cancers with official screening recommendations. Compliance rates with
   the recommendations were reviewed. Screening practices for other cancers
   (prostate cancer, melanoma, thyroid cancer, lung cancer, testicular
   cancer) were assessed.
   Results > A total of 133 questionnaires were analyzed. Despite a strong
   involvement of army general health practitioners, guidelines adherence
   rates (examination frequency, ages of screening beginning and ending)
   were of 4\% for cervical cancer, 7\% for breast cancer, and 37\% for
   colorectal cancer. Those rates are comparable to those reported with
   civilian general practitioners. For cancers without screening
   recommendation, practitioners felt highly concerned, especially for the
   most common cancers among the military population. One third of
   physicians stated that they had diagnosed a testicular cancer through
   routine screening.
   Conclusion > Military general health practitioners feel themselves
   concerned by solid cancer screening, and more particularly for cancers
   that are the most prevalent in young adults. However, current guidelines
   are neither known nor applied in routine.}},
Publisher = {{JOHN LIBBEY EUROTEXT LTD}},
Address = {{127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE}},
Type = {{Article}},
Language = {{French}},
Affiliation = {{Chargari, C (Reprint Author), Hop Instruct Armees Val de Grace, Serv Oncol \& Radiotherapie, 74 Blvd Port Royal, F-75005 Paris, France.
   Bellier, Thibault; Vedrine, Lionel; Chargari, Cyrus, Hop Instruct Armees Val de Grace, Serv Oncol \& Radiotherapie, F-75005 Paris, France.
   Vallard, Alexis; Espenel, Sophie; Langrand-Escure, Julien; Ben Mrad, Majed; Magne, Nicolas, Inst Cancerol Lucien Neuwirth, Dept Radiotherapie, F-42271 St Priest En Jarez, France.}},
DOI = {{10.1016/j.bulcan.2015.10.010}},
ISSN = {{0007-4551}},
EISSN = {{1769-6917}},
Keywords = {{Cancer screening; Military medicine; General practitioner; Guideline
   adherence}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Author-Email = {{chargari-vdg@hotmail.fr}},
ORCID-Numbers = {{Chargari, Cyrus/0000-0003-0119-3695}},
Cited-References = {{{[}Anonymous], 1996, ANN ENDOCRINOL-PARIS, V57, P526.
   {[}Anonymous], 2011, MED GEN DEP CANC.
   {[}Anonymous], 2010, EFF ARM FRANC 2009 2.
   Centre de coordination de depistage des cancers (APREMAS), 2009, DEP MAMM 1 2 LECT.
   Institut de Valle sanitaire, 2011, CANC TEST EV NAT VAR.
   Institut de Veille Sanitaire, 2011, EV PROGR DEP CANC SE.
   Institut de Veille Sanitaire, 2012, EV PROGR DEP ORG CAN.
   Institut de Veille Sanitaire, 2014, PATH CERV DEP SURV L.
   Institut de Veille Sanitaire, 2011, EV PROGR DEP CANC CO.
   Institut National du Cancer, 2010, SIT CANC FRANC 2010.
   Institut National du cancer, 2007, ETAT LIEUX DEP CANC.
   Kedzierewicz R, 2009, THESIS.
   Martinez-Lorenzi E, 2013, INCIDENCE 30 CHRONIC, V25, P599.
   Migliani R, 2013, CANC HEMOPATHIE ARME.}},
Number-of-Cited-References = {{14}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Bull. Cancer}},
Doc-Delivery-Number = {{DA8JN}},
Unique-ID = {{ISI:000368051000007}},
DA = {{2019-05-03}},
}

@article{ ISI:000459517600011,
Author = {Yahyazadeh, Sara and Mehraeen, Rahele},
Title = {{A COMPARISON OF THE DIAGNOSTIC VALUE OF MAGNETIC RESONANCE MAMMOGRAPHY
   VERSUS ULTRASOUND MAMMOGRAPHY IN MODERATE- AND HIGH-RISK BREAST CANCER
   PATIENTS}},
Journal = {{JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS}},
Year = {{2019}},
Volume = {{7}},
Number = {{53}},
Pages = {{5629-5633}},
Month = {{DEC 31}},
Abstract = {{BACKGROUND
   Due to the high prevalence of breast cancer, it is important to use
   screening methods for the diagnosis of early stages and faster treatment
   of this disease; better diagnosis should improve survival and quality of
   life for patients. Mammography, which is the preferred screening method
   for 40- to 70-year-old women, currently has limitations for the
   diagnosis of specific lesions. That is why screening with
   ultrasonography and magnetic resonance imaging (MRI) have recently
   received more attention. This study determined the sensitivity and
   specificity of these imaging methods in one hospital.
   MATERIALS AND METHODS
   This diagnostic descriptive study was conducted on women referred to
   surgical and gynaecological clinics of Rouhani Teaching Hospital in
   Babol, Northern Iran, who had a moderate or high risk of breast cancer.
   After MRI, the patients underwent ultrasonography and 6-month follow-up,
   with biopsies where needed. The researchers analysed the results to
   determine the diagnostic value of MRI and breast ultrasound, and to
   compare them.
   RESULTS
   A total of 106 women with an average age of 43.93 +/- 11.51 years were
   included. Out of 57 people who had Breast Imaging-Reporting and Data
   System (BIRADS) 3 by the ultrasound, 44 (77\%) people had BIRADS 3 on
   follow-up, but 13 people were in other groups. Of 59 people who had
   BIRADS 3 in the MRI, 54 (91\%) had BIRADS 3 after the follow-up too. The
   sensitivity, specificity, positive and negative predictive values (PPV
   and NPV), and accuracy of ultrasound were 91.7\%, 87.2\%, 47.8\%, 98.8\%
   and 87.7\%, respectively. These amounts were 100\%, 98.9\%, 92.3\%,
   100\% and 99.1\% for MRI, respectively. The difference for specificity,
   PPV and accuracy between ultrasound and MRI were significant (p=0.006,
   p=0.007, p=0.001, respectively), but not significant for sensitivity and
   NPV.
   CONCLUSION
   MRI has higher sensitivity, specificity and accuracy and less false
   positive and negative results for the early diagnosis of breast cancer
   in comparison with ultrasound.}},
Publisher = {{JOURNAL EVOLUTION MEDICAL \& DENTAL SCIENCES}},
Address = {{C/O AKSHANTALA ENTERPRISES, NO 65, 1ST FL, SAHUKAR CHENNIAH RD, MYSORE,
   KARNATAKA, 570 009, INDIA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Mehraeen, R (Reprint Author), Babol Univ Med Sci, Dept Paediat Radiol, Ganjafrooz St, Babol Sar, Mazandaran, Iran.
   Yahyazadeh, Sara, Babol Univ Med Sci, Sch Med, Student Res Comm, Babol Sar, Iran.
   Mehraeen, Rahele, Babol Univ Med Sci, Dept Paediat Radiol, Ganjafrooz St, Babol Sar, Mazandaran, Iran.}},
DOI = {{10.14260/jemds/2018/1245}},
ISSN = {{2278-4748}},
EISSN = {{2278-4802}},
Keywords = {{Breast Neoplasms; Diagnosis; Magnetic Resonance Imaging; Ultrasonography}},
Keywords-Plus = {{MRI; WOMEN; SURVEILLANCE; KNOWLEDGE; ACCURACY; US}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{rahelemehraeen4@gmail.com}},
Funding-Acknowledgement = {{Babol University of Medical Sciences}},
Funding-Text = {{We would like to thank the Vice Chancellor for the Research of Babol
   University of Medical Sciences for Financial Support.}},
Cited-References = {{Adarsh AD, 2017, J EVOL MED DENT SCI-, V6, P3524, DOI 10.14260/Jemds/2017/760.
   Banegas MP, 2012, J WOMENS HEALTH, V21, P101, DOI 10.1089/jwh.2010.2638.
   Bazzocchi M, 2000, Radiol Med, V100, P436.
   Benson JR, 2009, LANCET, V373, P1463, DOI 10.1016/S0140-6736(09)60316-0.
   Berg WA, 2004, RADIOLOGY, V233, P830, DOI 10.1148/radiol.2333031484.
   Berg WA, 2003, AM J ROENTGENOL, V180, P1225, DOI 10.2214/ajr.180.5.1801225.
   Berg WA, 2000, AM J ROENTGENOL, V174, P1769, DOI 10.2214/ajr.174.6.1741769.
   Berg WA, 2012, JAMA-J AM MED ASSOC, V307, P1394, DOI 10.1001/jama.2012.388.
   Chakkarapani R, 2018, J EVOL MED DENT SCI-, V7, P592, DOI 10.14260/jemds/2018/135.
   Corsetti V, 2011, EUR J CANCER, V47, P1021, DOI 10.1016/j.ejca.2010.12.002.
   Fentiman IS, 2001, INT J CLIN PRACT, V55, P527.
   Heywang-Kobrunner SH, 2013, BREAST, V22, pS77, DOI 10.1016/j.breast.2013.07.014.
   Houssami N, 2009, CA-CANCER J CLIN, V59, P290, DOI 10.3322/caac.20028.
   Kriege M, 2004, NEW ENGL J MED, V351, P427, DOI 10.1056/NEJMoa031759.
   Kuhl CK, 2005, J CLIN ONCOL, V23, P8469, DOI 10.1200/JCO.2004.00.4960.
   Li E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111217.
   Luczynska E, 2015, MED SCI MONITOR, V21, P1358, DOI 10.12659/MSM.893018.
   Mann RM, 2008, BREAST CANCER RES TR, V107, P1, DOI 10.1007/s10549-007-9528-5.
   Moodi M, 2013, ZUMS J, V21, P24.
   Nafissi N, 2012, J CANCER RES THER, V8, P46, DOI 10.4103/0973-1482.95173.
   Nagao Yasuko, 2003, Breast Cancer, V10, P228, DOI 10.1007/BF02966722.
   Nothacker M, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-335.
   Porter P, 2008, NEW ENGL J MED, V358, P213, DOI 10.1056/NEJMp0708307.
   Sabatino SA, 2012, AM J PREV MED, V43, P97, DOI 10.1016/j.amepre.2012.04.009.
   Sardanelli F, 2004, AM J ROENTGENOL, V183, P1149, DOI 10.2214/ajr.183.4.1831149.
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387.
   Strobel K, 2015, RADIOLOGY, V274, P343, DOI 10.1148/radiol.14140645.
   Tahergorabi Z, 2014, J BIRJAND U MED SCI, V21, P126.
   Ursin G, 2003, CANCER EPIDEM BIOMAR, V12, P332.
   Warner E, 2004, JAMA-J AM MED ASSOC, V292, P1317, DOI 10.1001/jama.292.11.1317.
   Yeh E, 2005, AM J ROENTGENOL, V184, P868, DOI 10.2214/ajr.184.3.01840868.}},
Number-of-Cited-References = {{31}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{268}},
Usage-Count-Since-2013 = {{268}},
Journal-ISO = {{J. Evol. Med. Dent. Sci.-JEMDS}},
Doc-Delivery-Number = {{HM5LQ}},
Unique-ID = {{ISI:000459517600011}},
DA = {{2019-05-03}},
}

@article{ ISI:000462645700071,
Author = {Jiang, Yang and Lin, Lili and Zhong, Shen and Cai, Yangjun and Zhang,
   Fen and Wang, Xiaobo and Miao, Rongrong and Zhang, Baodan and Gao,
   Shenmeng and Hu, Xiaoqu},
Title = {{Overexpression of novel lncRNA NLIPMT inhibits metastasis by reducing phosphorylated glycogen synthase kinase 3 in breast cancer}},
Journal = {{JOURNAL OF CELLULAR PHYSIOLOGY}},
Year = {{2019}},
Volume = {{234}},
Number = {{7}},
Pages = {{10698-10708}},
Month = {{JUL}},
Abstract = {{Long noncoding RNAs (lncRNAs) are considered as regulators of gene
   expression in cancers. However, cancer profiling has little focused on
   noncoding genes. Here, we reported that RP11-115N4.1 (here renamed novel
   lncRNA inhibiting proliferation and metastasis {[}NLIPMT]) was
   downregulated in breast cancer tissues. Ectopic expression of NLIPMT
   inhibited mammary cell proliferation, motility in vitro. Moreover,
   lnc-NLIPMT reduced the growth of implanted MDA-MB-231 cells in vivo.
   Mechanistically, glycogen synthase kinase 3 (GSK3) was identified as an
   effector protein regulated by lnc-NLIPMT. Inhibition of GSK3 activity
   restored NLIPMT-induced inhibition of proliferation and motility in
   breast cancer cells. These data reveal that lnc-NLIPMT functions as a
   driver of breast cancer progression and might serve as a potential
   target for antimetastatic therapies.}},
Publisher = {{WILEY}},
Address = {{111 RIVER ST, HOBOKEN 07030-5774, NJ USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Hu, XQ (Reprint Author), Wenzhou Med Univ, Affiliated Hosp 1, Dept Thyroid \& Breast Surg, Wenzhou 325000, Zhejiang, Peoples R China.
   Gao, SM (Reprint Author), Wenzhou Med Univ, Affiliated Hosp 1, Lab Internal Med, Wenzhou 325000, Zhejiang, Peoples R China.
   Jiang, Yang; Lin, Lili; Cai, Yangjun; Zhang, Fen; Wang, Xiaobo; Miao, Rongrong; Zhang, Baodan; Hu, Xiaoqu, Wenzhou Med Univ, Affiliated Hosp 1, Dept Thyroid \& Breast Surg, Wenzhou 325000, Zhejiang, Peoples R China.
   Zhong, Shen, Kecheng Peoples Hosp, Dept Colorectal \& Anal Surg, Quzhou, Zhejiang, Peoples R China.
   Gao, Shenmeng, Wenzhou Med Univ, Affiliated Hosp 1, Lab Internal Med, Wenzhou 325000, Zhejiang, Peoples R China.}},
DOI = {{10.1002/jcp.27738}},
ISSN = {{0021-9541}},
EISSN = {{1097-4652}},
Keywords = {{breast cancer; glycogen; long noncoding RNA; migration; proliferation;
   synthase kinase 3}},
Keywords-Plus = {{LONG NONCODING RNAS; EXPRESSION; GSK-3-BETA;
   GLYCOGEN-SYNTHASE-KINASE-3-BETA; CELLS; PROLIFERATION; OPPORTUNITIES;
   LOCALIZATION; INACTIVATION; CHALLENGES}},
Research-Areas = {{Cell Biology; Physiology}},
Web-of-Science-Categories  = {{Cell Biology; Physiology}},
Author-Email = {{gaoshenmeng77@126.com
   drhxj@126.com}},
Funding-Acknowledgement = {{National Natural Science Foundation of China {[}81572580]}},
Funding-Text = {{National Natural Science Foundation of China, Grant/Award Number:
   81572580}},
Cited-References = {{Armanious H, 2010, HUM PATHOL, V41, P1657, DOI 10.1016/j.humpath.2010.04.015.
   Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154.
   Beurel E, 2015, PHARMACOL THERAPEUT, V148, P114, DOI 10.1016/j.pharmthera.2014.11.016.
   Bianchini G, 2016, NAT REV CLIN ONCOL, V13, P674, DOI 10.1038/nrclinonc.2016.66.
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983.
   Darrington RS, 2012, INT J CANCER, V131, pE872, DOI 10.1002/ijc.27620.
   Dembowy J, 2015, ONCOGENE, V34, P3514, DOI 10.1038/onc.2014.279.
   Farago M, 2005, CANCER RES, V65, P5792, DOI 10.1158/0008-5472.CAN-05-1021.
   Garcea G, 2007, CURR CANCER DRUG TAR, V7, P209, DOI 10.2174/156800907780618266.
   Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981.
   Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192.
   Jakubowska A, 2012, BRIT J CANCER, V106, P2016, DOI 10.1038/bjc.2012.160.
   Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634.
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412.
   Leis H, 2002, MOL CARCINOGEN, V35, P180, DOI 10.1002/mc.10087.
   Lennox KA, 2016, NUCLEIC ACIDS RES, V44, P863, DOI 10.1093/nar/gkv1206.
   Li WJ, 2017, J CLIN INVEST, V127, P3427, DOI 10.1172/JCI94233.
   Liu PY, 2017, CELL CYCLE, V16, P776, DOI 10.1080/15384101.2017.1295193.
   Luo YH, 2018, J CELL BIOCHEM, V119, P691, DOI 10.1002/jcb.26232.
   Ma C, 2007, CANCER RES, V67, P7756, DOI 10.1158/0008-5472.CAN-06-4665.
   Manoukian AS, 2002, ADV CANCER RES, V84, P203, DOI 10.1016/S0065-230X(02)84007-6.
   McCubrey JA, 2014, LEUKEMIA, V28, P15, DOI 10.1038/leu.2013.184.
   Mills CN, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00047.
   Mukherjee S, 2006, CANCER BIOL THER, V5, P674, DOI 10.4161/cbt.5.6.2906.
   Mulholland DJ, 2006, ONCOGENE, V25, P329, DOI 10.1038/sj.onc.1209020.
   Mullor JL, 2002, TRENDS CELL BIOL, V12, P562, DOI 10.1016/S0962-8924(02)02405-4.
   Oliveira NCS, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15027701.
   Ougolkov Andrei V, 2006, Future Oncol, V2, P91, DOI 10.2217/14796694.2.1.91.
   Rehman I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030885.
   Rinn J. L., 2014, COLD SPRING HARBOR P, V6.
   Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902.
   Sanchez Y, 2013, NUCLEIC ACID THER, V23, P15, DOI 10.1089/nat.2012.0414.
   Sas-Chen A, 2016, EMBO MOL MED, V8, P1052, DOI 10.15252/emmm.201606198.
   Schmole AC, 2010, BIOORGAN MED CHEM, V18, P6785, DOI 10.1016/j.bmc.2010.07.045.
   Schroder C, 2013, J CANCER RES CLIN, V139, P1745, DOI 10.1007/s00432-013-1496-z.
   Serviss JT, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00234.
   Shakoori A, 2007, CANCER SCI, V98, P1388, DOI 10.1111/j.1349-7006.2007.00545.x.
   Spizzo R, 2012, ONCOGENE, V31, P4577, DOI 10.1038/onc.2011.621.
   Sun M, 2015, MOL CELL, V59, P698, DOI 10.1016/j.molcel.2015.06.023.
   Sun M, 2015, ENDOCR REV, V36, P25, DOI 10.1210/er.2014-1034.
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007.
   Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002.
   Vincent T, 2008, ONCOGENE, V27, P5254, DOI 10.1038/onc.2008.152.
   Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018.
   Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764.
   Yoon JH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3939.}},
Number-of-Cited-References = {{46}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{6}},
Usage-Count-Since-2013 = {{6}},
Journal-ISO = {{J. Cell. Physiol.}},
Doc-Delivery-Number = {{HQ8AL}},
Unique-ID = {{ISI:000462645700071}},
DA = {{2019-05-03}},
}

@article{ ISI:000316992100002,
Author = {Gao, Jianjiong and Aksoy, Buelent Arman and Dogrusoz, Ugur and Dresdner,
   Gideon and Gross, Benjamin and Sumer, S. Onur and Sun, Yichao and
   Jacobsen, Anders and Sinha, Rileen and Larsson, Erik and Cerami, Ethan
   and Sander, Chris and Schultz, Nikolaus},
Title = {{Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal}},
Journal = {{SCIENCE SIGNALING}},
Year = {{2013}},
Volume = {{6}},
Number = {{269}},
Month = {{APR 2}},
Abstract = {{The cBioPortal for Cancer Genomics (http://cbioportal.org) provides a
   Web resource for exploring, visualizing, and analyzing multidimensional
   cancer genomics data. The portal reduces molecular profiling data from
   cancer tissues and cell lines into readily understandable genetic,
   epigenetic, gene expression, and proteomic events. The query interface
   combined with customized data storage enables researchers to
   interactively explore genetic alterations across samples, genes, and
   pathways and, when available in the underlying data, to link these to
   clinical outcomes. The portal provides graphical summaries of gene-level
   data from multiple platforms, network visualization and analysis,
   survival analysis, patient-centric queries, and software programmatic
   access. The intuitive Web interface of the portal makes complex cancer
   genomics profiles accessible to researchers and clinicians without
   requiring bioinformatics expertise, thus facilitating biological
   discoveries. Here, we provide a practical guide to the analysis and
   visualization features of the cBioPortal for Cancer Genomics.}},
Publisher = {{AMER ASSOC ADVANCEMENT SCIENCE}},
Address = {{1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Gao, JJ (Reprint Author), Mem Sloan Kettering Canc Ctr, Computat Biol Ctr, New York, NY 10065 USA.
   Gao, Jianjiong; Aksoy, Buelent Arman; Dresdner, Gideon; Gross, Benjamin; Sumer, S. Onur; Sun, Yichao; Jacobsen, Anders; Sinha, Rileen; Cerami, Ethan; Sander, Chris; Schultz, Nikolaus, Mem Sloan Kettering Canc Ctr, Computat Biol Ctr, New York, NY 10065 USA.
   Dogrusoz, Ugur, Bilkent Univ, Dept Comp Engn, TR-06800 Ankara, Turkey.
   Larsson, Erik, Univ Gothenburg, Dept Med Biochem \& Cell Biol, Inst Biomed, S-40530 Gothenburg, Sweden.
   Cerami, Ethan, Blueprint Med, Cambridge, MA 02142 USA.}},
DOI = {{10.1126/scisignal.2004088}},
Article-Number = {{pl1}},
ISSN = {{1945-0877}},
EISSN = {{1937-9145}},
Keywords-Plus = {{RECEPTOR TYROSINE KINASE; OVARIAN-CARCINOMA; NETWORK; PATHWAYS;
   DATABASE; TARGETS; GENES; MUTATIONS; CYTOSCAPE; THERAPY}},
Research-Areas = {{Biochemistry \& Molecular Biology; Cell Biology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology; Cell Biology}},
Author-Email = {{cbioportal@cbio.mskcc.org}},
ResearcherID-Numbers = {{Gao, JianJiong/B-5673-2016
   Jacobsen Skanderup, Anders/K-1081-2013
   Polat, Ibrahim Halil/R-3739-2017
   }},
ORCID-Numbers = {{Gao, JianJiong/0000-0002-5739-1781
   Jacobsen Skanderup, Anders/0000-0001-6847-4980
   Polat, Ibrahim Halil/0000-0003-2196-6667
   Sinha, Rileen/0000-0001-5497-5055}},
Funding-Acknowledgement = {{NCI NIH HHS {[}R21CA135870, U24CA143840, U24 CA143840, R01 CA132744, R21
   CA135870]; NCRR NIH HHS {[}P41 RR031228]; NIGMS NIH HHS {[}P41 GM103504,
   GM103504]}},
Cited-References = {{Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894.
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003.
   Barretina J, 2010, NAT GENET, V42, P715, DOI 10.1038/ng.619.
   Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166.
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095.
   Cerami EG, 2011, NUCLEIC ACIDS RES, V39, pD685, DOI 10.1093/nar/gkq1039.
   Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385.
   Ciriello G, 2012, GENOME RES, V22, P398, DOI 10.1101/gr.125567.111.
   Finn RD, 2010, NUCLEIC ACIDS RES, V38, pD211, DOI 10.1093/nar/gkp985.
   Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299.
   Gundem G, 2010, NAT METHODS, V7, P92, DOI 10.1038/nmeth0210-92.
   Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404.
   Hudson TJ, 2010, NATURE, V464, P993, DOI 10.1038/nature08987.
   Hynes NE, 2001, J MAMMARY GLAND BIOL, V6, P141, DOI 10.1023/A:1009528918064.
   Knox C, 2011, NUCLEIC ACIDS RES, V39, pD1035, DOI 10.1093/nar/gkq1126.
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412.
   Le Novere N, 2009, NAT BIOTECHNOL, V27, P735, DOI 10.1038/nbt.1558.
   Lopes CT, 2010, BIOINFORMATICS, V26, P2347, DOI 10.1093/bioinformatics/btq430.
   Matthews L, 2009, NUCLEIC ACIDS RES, V37, pD619, DOI 10.1093/nar/gkn863.
   Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504.
   Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41.
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252.
   Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892.
   Rask-Andersen M, 2011, NAT REV DRUG DISCOV, V10, P579, DOI 10.1038/nrd3478.
   Raymond E, 2000, DRUGS, V60, P15, DOI 10.2165/00003495-200060001-00002.
   Reva B, 2011, NUCLEIC ACIDS RES, V39, pE118, DOI 10.1093/nar/gkr407.
   Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112.
   Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754.
   Sanborn JZ, 2011, NUCLEIC ACIDS RES, V39, pD951, DOI 10.1093/nar/gkq1113.
   Schaefer CF, 2009, NUCLEIC ACIDS RES, V37, pD674, DOI 10.1093/nar/gkn653.
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303.
   Sheehan KM, 2005, MOL CELL PROTEOMICS, V4, P346, DOI 10.1074/mcp.T500003-MCP200.
   Takarabe M, 2011, J CHEM INF MODEL, V51, P2977, DOI 10.1021/ci200367w.
   Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026.}},
Number-of-Cited-References = {{34}},
Times-Cited = {{2983}},
Usage-Count-Last-180-days = {{26}},
Usage-Count-Since-2013 = {{65}},
Journal-ISO = {{Sci. Signal.}},
Doc-Delivery-Number = {{117ZM}},
Unique-ID = {{ISI:000316992100002}},
OA = {{Green Published, Green Accepted}},
DA = {{2019-05-03}},
}

@article{ ISI:000259891500003,
Author = {Chen, Xi and Ba, Yi and Ma, Lijia and Cai, Xing and Yin, Yuan and Wang,
   Kehui and Guo, Jigang and Zhang, Yujing and Chen, Jiangning and Guo,
   Xing and Li, Qibin and Li, Xiaoying and Wang, Wenjing and Zhang, Yan and
   Wang, Jin and Jiang, Xueyuan and Xiang, Yang and Xu, Chen and Zheng,
   Pingping and Zhang, Juanbin and Li, Ruiqiang and Zhang, Hongjie and
   Shang, Xiaobin and Gong, Ting and Ning, Guang and Wang, Jun and Zen, Ke
   and Zhang, Junfeng and Zhang, Chen-Yu},
Title = {{Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases}},
Journal = {{CELL RESEARCH}},
Year = {{2008}},
Volume = {{18}},
Number = {{10}},
Pages = {{997-1006}},
Month = {{OCT}},
Abstract = {{Dysregulated expression of microRNAs (miRNAs) in various tissues has
   been associated with a variety of diseases, including cancers. Here we
   demonstrate that miRNAs are present in the serum and plasma of humans
   and other animals such as mice, rats, bovine fetuses, calves, and
   horses. The levels of miRNAs in serum are stable, reproducible, and
   consistent among individuals of the same species. Employing Solexa, we
   sequenced all serum miRNAs of healthy Chinese subjects and found over
   100 and 91 serum miRNAs in male and female subjects, respectively. We
   also identified specific expression patterns of serum miRNAs for lung
   cancer, colorectal cancer, and diabetes, providing evidence that serum
   miRNAs contain fingerprints for various diseases. Two non-small cell
   lung cancer-specific serum miRNAs obtained by Solexa were further
   validated in an independent trial of 75 healthy donors and 152 cancer
   patients, using quantitative reverse transcription polymerase chain
   reaction assays. Through these analyses, we conclude that serum miRNAs
   can serve as potential biomarkers for the detection of various cancers
   and other diseases.}},
Publisher = {{INST BIOCHEMISTRY \& CELL BIOLOGY}},
Address = {{SIBS, CAS, 319 YUEYAND ROAD, SHANGHAI, 200031, PEOPLES R CHINA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Zhang, CY (Reprint Author), Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, Jiangsu Diabet Ctr, 22 Hankou Rd, Nanjing 210093, Jiangsu, Peoples R China.
   Chen, Xi; Cai, Xing; Yin, Yuan; Wang, Kehui; Guo, Jigang; Zhang, Yujing; Chen, Jiangning; Guo, Xing; Zhang, Yan; Wang, Jin; Jiang, Xueyuan; Xiang, Yang; Xu, Chen; Zhang, Hongjie; Zen, Ke; Zhang, Junfeng; Zhang, Chen-Yu, Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, Jiangsu Diabet Ctr, Nanjing 210093, Jiangsu, Peoples R China.
   Ba, Yi; Shang, Xiaobin; Gong, Ting, Tianjin Med Univ Canc Inst \& Hosp, Tianjin 300000, Peoples R China.
   Ma, Lijia; Li, Qibin; Zheng, Pingping; Zhang, Juanbin; Li, Ruiqiang; Wang, Jun, Beijing Genom Inst, Shenzhen 518083, Peoples R China.
   Ma, Lijia; Li, Qibin; Wang, Jun, Chinese Acad Sci, Beijing Inst Genom, Beijing 101300, Peoples R China.
   Li, Xiaoying; Ning, Guang, Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Endocrine \& Metab Dis, Shanghai 200025, Peoples R China.
   Wang, Wenjing, Shanghai Municipal Ctr Dis Control \& Prevent, Shanghai 200336, Peoples R China.}},
DOI = {{10.1038/cr.2008.282}},
ISSN = {{1001-0602}},
Keywords = {{serum-microRNA; expression profile; fingerprint; blood-based biomarker;
   Solexa; cancers; diabetes}},
Keywords-Plus = {{TUMOR-MARKERS; COLON-CANCER; IDENTIFICATION; SIGNATURES; PLASMA; RNA}},
Research-Areas = {{Cell Biology}},
Web-of-Science-Categories  = {{Cell Biology}},
Author-Email = {{wangj@genomics.org.cn
   kzen@nju.edu.cn
   jfzhang@nju.edu.cn
   cyzhang@nju.edu.cn}},
ResearcherID-Numbers = {{Wang, Jun/C-8434-2016
   }},
ORCID-Numbers = {{Wang, Jun/0000-0002-8540-8931
   Wang, Jun/0000-0002-2113-5874
   Zheng, Pingping/0000-0002-6059-8919}},
Funding-Acknowledgement = {{National Natural Science Foundation of China {[}30225037, 30471991,
   30570731]; National Basic Research Program of China {[}2006CB503909,
   2004CB518603]; Natural Science Foundation of Jiangsu Province
   {[}BK2004082, BK2006714]}},
Funding-Text = {{We thank Drs Fengyong Liu and Sheng Luan at UC Berkeley, USA, for their
   discussion and help with the writing of the manuscript. This work was
   supported by grants from the National Natural Science Foundation of
   China (no. 30225037, 30471991, 30570731), National Basic Research
   Program of China (973 Program) (no. 2006CB503909, 2004CB518603), the ``
   111{''} Project, and the Natural Science Foundation of Jiangsu Province
   (no. BK2004082, BK2006714).}},
Cited-References = {{Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997.
   Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178.
   Chim SSC, 2008, CLIN CHEM, V54, P482, DOI 10.1373/clinchem.2007.097972.
   Duffy MJ, 2007, EUR J INTERN MED, V18, P175, DOI 10.1016/j.ejim.2006.12.001.
   Duffy MJ, 2001, CRIT REV CL LAB SCI, V38, P225, DOI 10.1080/20014091084218.
   El-Hefnawy T, 2004, CLIN CHEM, V50, P564, DOI 10.1373/clinchem.2003.028506.
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840.
   Garofalo M, 2008, ONCOGENE, V27, P3845, DOI 10.1038/onc.2008.6.
   Gottardo F, 2007, UROL ONCOL-SEMIN ORI, V25, P387, DOI 10.1016/j.urolonc.2007.01.019.
   Hafner M, 2008, METHODS, V44, P3, DOI 10.1016/j.ymeth.2007.09.009.
   He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102.
   Lawrie CH, 2008, BRIT J HAEMATOL, V141, P672, DOI 10.1111/j.1365-2141.2008.07077.x.
   Leman ES, 2007, CANCER RES, V67, P5600, DOI 10.1158/0008-5472.CAN-07-0649.
   Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105.
   ROULSTON JE, 1990, BRIT J SURG, V77, P961, DOI 10.1002/bjs.1800770903.
   Tang FC, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj009.
   Thomas CMG, 2001, INT J BIOL MARKER, V16, P73.
   Tsang JCH, 2007, PATHOLOGY, V39, P197, DOI 10.1080/00313020701230831.
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103.
   Ward DG, 2006, BRIT J CANCER, V94, P1898, DOI 10.1038/sj.bjc.6603188.}},
Number-of-Cited-References = {{20}},
Times-Cited = {{2538}},
Usage-Count-Last-180-days = {{30}},
Usage-Count-Since-2013 = {{533}},
Journal-ISO = {{Cell Res.}},
Doc-Delivery-Number = {{358BN}},
Unique-ID = {{ISI:000259891500003}},
OA = {{Bronze}},
DA = {{2019-05-03}},
}

@article{ ISI:A1997XP01400037,
Author = {Ambrosini, G and Adida, C and Altieri, DC},
Title = {{A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma}},
Journal = {{NATURE MEDICINE}},
Year = {{1997}},
Volume = {{3}},
Number = {{8}},
Pages = {{917-921}},
Month = {{AUG}},
Abstract = {{Inhibitors of programmed cell death (apoptosis) aberrantly prolonging
   cell viability may contribute to cancer(1) by facilitating the
   insurgence of mutations and by promoting resistance to therapy(2).
   Despite the identification of several new apoptosis inhibitors related
   to bcl-2(2,3) or to the baculovirus IAP gene(4-9), it is not clear
   whether apoptosis inhibition plays a general role in neoplasia. Here, we
   describe a new human gene encoding a structurally unique IAP apoptosis
   inhibitor, designated survivin. Survivin contains a single baculovirus
   IAP repeat and lacks a carboxyl-terminal RING finger. Present during
   fetal development, survivin is undetectable in terminally differentiated
   adult tissues. However, survivin becomes prominently expressed in
   transformed cell lines and in all the most common human cancers of lung,
   colon, pancreas, prostate and breast, in vivo. Survivin is also found in
   approximately 50\% of high-grade non-Hodgkin's lymphomas (centroblastic,
   immunoblastic), but not in low-grade lymphomas (lymphocytic).
   Recombinant expression of survivin counteracts apoptosis of B lymphocyte
   precursors deprived of interleukin 3 (IL-3). These findings suggest that
   apoptosis inhibition may be a general feature of neoplasia and identify
   survivin as a potential new target for apoptosis-based therapy in cancer
   and lymphoma.}},
Publisher = {{NATURE PUBLISHING CO}},
Address = {{345 PARK AVE SOUTH, NEW YORK, NY 10010-1707}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{YALE UNIV,SCH MED,DEPT PATHOL,BOYER CTR MOL MED,NEW HAVEN,CT 06536.}},
DOI = {{10.1038/nm0897-917}},
ISSN = {{1078-8956}},
Keywords-Plus = {{CELL-DEATH; BCL-2; PROTEIN; STRAND}},
Research-Areas = {{Biochemistry \& Molecular Biology; Cell Biology; Research \&
   Experimental Medicine}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology; Cell Biology; Medicine, Research \&
   Experimental}},
Funding-Acknowledgement = {{NHLBI NIH HHS {[}R01 HL 43773, HL 54131]}},
Cited-References = {{Adida C, 1996, BLOOD, V88, P1457.
   ALTIERI DC, 1995, FASEB J, V9, P860.
   ASCASO R, 1994, EUR J IMMUNOL, V24, P537, DOI 10.1002/eji.1830240307.
   BIRNBAUM MJ, 1994, J VIROL, V68, P2521.
   CELANO P, 1992, J BIOL CHEM, V267, P15092.
   Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x.
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9.
   GRAHAM GJ, 1995, J THEOR BIOL, V175, P71, DOI 10.1006/jtbi.1995.0122.
   Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7.
   HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961.
   Jiang SX, 1996, AM J PATHOL, V148, P837.
   KHOCHBIN S, 1989, EMBO J, V8, P4107, DOI 10.1002/j.1460-2075.1989.tb08595.x.
   KIMMELMAN D, 1989, CELL, V59, P687.
   KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180.
   LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128.
   LEBRUN DP, 1993, AM J PATHOL, V142, P743.
   Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0.
   REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1.
   Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3.
   ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1.
   THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464.
   Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974.
   Yang E, 1996, BLOOD, V88, P386.}},
Number-of-Cited-References = {{23}},
Times-Cited = {{2466}},
Usage-Count-Last-180-days = {{13}},
Usage-Count-Since-2013 = {{167}},
Journal-ISO = {{Nat. Med.}},
Doc-Delivery-Number = {{XP014}},
Unique-ID = {{ISI:A1997XP01400037}},
DA = {{2019-05-03}},
}

@article{ ISI:000073956700008,
Author = {Tsujii, M and Kawano, S and Tsuji, S and Sawaoka, H and Hori, M and
   DuBois, RN},
Title = {{Cyclooxygenase regulates angiogenesis induced by colon cancer cells}},
Journal = {{CELL}},
Year = {{1998}},
Volume = {{93}},
Number = {{5}},
Pages = {{705-716}},
Month = {{MAY 29}},
Abstract = {{To explore the role of cyclooxygenase (COX) in endothelial cell
   migration and angiogenesis, we have used two in vitro model systems
   involving coculture of endothelial cells with colon carcinoma cells.
   COX-2-overexpressing cells produce prostaglandins, proangiogenic
   factors, and stimulate both endothelial migration and tube formation,
   while control cells have little activity. The effect is inhibited by
   antibodies to combinations of angiogenic factors, by NS-398 (a selective
   COX-2 inhibitor), and by aspirin. NS-398 does not inhibit production of
   angiogenic factors or angiogenesis induced by COX-2-negative cells.
   Treatment of endothelial cells with aspirin or a COX-1 antisense
   oligonucleotide inhibits COX-1 activity/expression and suppresses tube
   formation. Cyclooxygenase regulates colon carcinoma-induced angiogenesis
   by two mechanisms: COX-2 can modulate production of angiogenic factors
   by colon cancer cells, while COX-1 regulates angiogenesis in endothelial
   cells.}},
Publisher = {{CELL PRESS}},
Address = {{1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Tsujii, M (Reprint Author), Vanderbilt Univ, Med Ctr, Dept Med, VA Med Ctr, Nashville, TN 37232 USA.
   Vanderbilt Univ, Med Ctr, Dept Med, VA Med Ctr, Nashville, TN 37232 USA.
   Vanderbilt Univ, Med Ctr, Dept Cell Biol, Nashville, TN 37232 USA.
   Osaka Univ, Sch Med, Dept Med 1, Osaka 5650871, Japan.}},
DOI = {{10.1016/S0092-8674(00)81433-6}},
ISSN = {{0092-8674}},
Keywords-Plus = {{PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-1; MICROVASCULAR ENDOTHELIAL-CELLS;
   GROWTH-FACTOR; EXPRESSION; DIFFERENTIATION; MODULATION; MIGRATION;
   MATRIX; MODEL}},
Research-Areas = {{Biochemistry \& Molecular Biology; Cell Biology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology; Cell Biology}},
Funding-Acknowledgement = {{NCEH CDC HHS {[}NIEHS-00267]; NIDDK NIH HHS {[}DK-47297]}},
Cited-References = {{ABE T, 1993, J CLIN INVEST, V92, P54, DOI 10.1172/JCI116599.
   BRANNON TS, 1994, J CLIN INVEST, V93, P2230, DOI 10.1172/JCI117220.
   Breyer MD, 1996, J AM SOC NEPHROL, V7, P8.
   Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657.
   DuBois RN, 1998, CARCINOGENESIS, V19, P49, DOI 10.1093/carcin/19.1.49.
   DuBois RN, 1996, CANCER RES, V56, P733.
   FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4.
   Forman BM, 1996, ANN NY ACAD SCI, V804, P266, DOI 10.1111/j.1749-6632.1996.tb18621.x.
   GIARDIELLO FM, 1995, EUR J CANCER, V31A, P1071, DOI 10.1016/0959-8049(95)00137-8.
   HOFF T, 1993, FEBS LETT, V320, P38, DOI 10.1016/0014-5793(93)81653-H.
   Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q.
   Kawamori T, 1998, CANCER RES, V58, P409.
   Koolwijk P, 1996, J CELL BIOL, V132, P1177, DOI 10.1083/jcb.132.6.1177.
   MASUDA E, 1992, AM J PHYSIOL, V262, pG785.
   MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648.
   MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239.
   Narko K, 1997, J BIOL CHEM, V272, P21455, DOI 10.1074/jbc.272.34.21455.
   Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1.
   Papapetropoulos A, 1997, AM J PATHOL, V150, P1835.
   Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2.
   Sankar S, 1996, J CLIN INVEST, V97, P1436, DOI 10.1172/JCI118565.
   Seed MP, 1997, CANCER RES, V57, P1625.
   Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400.
   Shiff SJ, 1997, GASTROENTEROLOGY, V113, P1992, DOI 10.1016/S0016-5085(97)99999-6.
   SKOBE M, 1997, NAT MED, V3, P122.
   Smalley W E, 1997, Adv Pharmacol, V39, P1, DOI 10.1016/S1054-3589(08)60067-8.
   SMITH CJ, 1993, BIOCHEM BIOPH RES CO, V192, P787, DOI 10.1006/bbrc.1993.1483.
   Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336.
   TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2.
   Ueda N, 1997, BBA-LIPID LIPID MET, V1344, P103, DOI 10.1016/S0005-2760(96)00131-2.
   WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044.
   WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857.
   WILLIAMS CS, 1997, J CLIN INVEST, V100, P1.
   Yamazaki K, 1996, IN VIVO, V10, P459.
   YANG EY, 1990, J CELL BIOL, V111, P731, DOI 10.1083/jcb.111.2.731.}},
Number-of-Cited-References = {{35}},
Times-Cited = {{1930}},
Usage-Count-Last-180-days = {{4}},
Usage-Count-Since-2013 = {{80}},
Journal-ISO = {{Cell}},
Doc-Delivery-Number = {{ZR264}},
Unique-ID = {{ISI:000073956700008}},
OA = {{Bronze}},
DA = {{2019-05-03}},
}

@article{ ISI:000242953000009,
Author = {Neve, Richard M. and Chin, Koei and Fridlyand, Jane and Yeh, Jennifer
   and Baehner, Frederick L. and Fevr, Tea and Clark, Laura and Bayani,
   Nora and Coppe, Jean-Philippe and Tong, Frances and Speed, Terry and
   Spellman, Paul T. and DeVries, Sandy and Lapuk, Anna and Wang, Nick J.
   and Kuo, Wen-Lin and Stilwell, Jackie L. and Pinkel, Daniel and
   Albertson, Donna G. and Waldman, Frederic M. and McCormick, Frank and
   Dickson, Robert B. and Johnson, Michael D. and Lippman, Marc and Ethier,
   Stephen and Gazdar, Adi and Gray, Joe W.},
Title = {{A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes}},
Journal = {{CANCER CELL}},
Year = {{2006}},
Volume = {{10}},
Number = {{6}},
Pages = {{515-527}},
Month = {{DEC}},
Abstract = {{Recent studies suggest that thousands of genes may contribute to breast
   cancer pathophysiologies when deregulated by genomic or epigenomic
   events. Here, we describe a model ``system{''} to appraise the
   functional contributions of these genes to breast cancer subsets. In
   general, the recurrent genomic and transcriptional characteristics of 51
   breast cancer cell lines mirror those of 145 primary breast tumors,
   although some significant differences are documented. The cell lines
   that comprise the system also exhibit the substantial genomic,
   transcriptional, and biological heterogeneity found in primary tumors.
   We show, using Trastuzumab (Herceptin) monotherapy as an example, that
   the system can be used to identify molecular features that predict or
   indicate response to targeted therapies or other physiological
   perturbations.}},
Publisher = {{CELL PRESS}},
Address = {{50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Neve, RM (Reprint Author), Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94270 USA.
   Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94270 USA.
   Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA.
   Univ Calif Berkeley, Dept Stat, Berkeley, CA 94720 USA.
   Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Detroit, MI USA.
   Univ Texas, SW Med Ctr, Dallas, TX 75390 USA.
   Univ Calif San Francisco, Div Biostat, Dept Epidemiol \& Biostat, San Francisco, CA 94143 USA.
   Georgetown Univ, Sch Med, Washington, DC 20057 USA.
   Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA.
   Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA.}},
DOI = {{10.1016/j.ccr.2006.10.008}},
ISSN = {{1535-6108}},
EISSN = {{1878-3686}},
Keywords-Plus = {{COMPARATIVE GENOMIC HYBRIDIZATION; GENE-EXPRESSION PATTERNS; MAMMARY
   EPITHELIAL-CELLS; COPY NUMBER; MOLECULAR PORTRAITS; SOLID TUMORS;
   IN-VITRO; CARCINOMAS; RESISTANCE; REVEALS}},
Research-Areas = {{Oncology; Cell Biology}},
Web-of-Science-Categories  = {{Oncology; Cell Biology}},
Author-Email = {{rmneve@lbl.gov}},
ResearcherID-Numbers = {{Speed, Terence/B-8085-2009}},
ORCID-Numbers = {{Speed, Terence/0000-0002-5403-7998}},
Funding-Acknowledgement = {{NCI NIH HHS {[}CA090788, P50 CA058207, U54 CA112970-05, CA 58207, U54
   CA112970, CA112970, U54 CA090788]}},
Cited-References = {{Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100.
   Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215.
   ALIMANDI M, 1995, ONCOGENE, V10, P1813.
   Beck GR, 2001, CELL GROWTH DIFFER, V12, P61.
   Carter TA, 2005, P NATL ACAD SCI USA, V102, P11011, DOI 10.1073/pnas.0504952102.
   CATTORETTI G, 1988, BRIT J CANCER, V57, P353, DOI 10.1038/bjc.1988.81.
   Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254.
   Chen KN, 2004, IEEE ELECTR DEVICE L, V25, P10, DOI 10.1109/LED.2003.821591.
   Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009.
   Chung CH, 2002, NAT GENET, V32, P533, DOI 10.1038/ng1038.
   Dontu G, 2003, CELL PROLIFERAT, V36, P59, DOI 10.1046/j.1365-2184.36.s.1.6.x.
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803.
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863.
   El-Rehim DMA, 2004, J PATHOL, V203, P661, DOI 10.1002/path.1559.
   ETHIER SP, 1993, CANCER RES, V53, P627.
   Feldman RJ, 2003, CANCER RES, V63, P4626.
   Fridlyand J, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-96.
   Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L.
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9.
   Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771.
   Hyman E, 2002, CANCER RES, V62, P6240.
   Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609.
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249.
   Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902.
   Jeffrey Stefanie S, 2005, J Natl Compr Canc Netw, V3, P291.
   Jones C, 2004, CANCER RES, V64, P3037, DOI 10.1158/0008-5472.CAN-03-2028.
   KALLIONIEMI OP, 1994, GENE CHROMOSOME CANC, V10, P231, DOI 10.1002/gcc.2870100403.
   Korsching E, 2002, LAB INVEST, V82, P1525, DOI 10.1097/01.LAB.0000038508.86221.B3.
   Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101.
   Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000.
   Larramendy ML, 2000, CANCER GENET CYTOGEN, V119, P132, DOI 10.1016/S0165-4608(99)00226-5.
   Lim KC, 2000, NAT GENET, V25, P209, DOI 10.1038/76080.
   Loo LWM, 2004, CANCER RES, V64, P8541, DOI 10.1158/0008-5472.CAN-04-1992.
   Mahon FX, 2000, BLOOD, V96, P1070.
   Nahta R, 2004, CANCER RES, V64, P3981, DOI 10.1158/0008-5472.CAN-03-3900.
   Neve RM, 2000, ONCOGENE, V19, P1647, DOI 10.1038/sj.onc.1203470.
   NEVE RM, 2004, DIS BREAST, P383.
   Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220.
   Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212.
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093.
   Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999.
   Radisky DC, 2004, SCIENCE, V303, P775, DOI 10.1126/science.1094412.
   Roylance R, 1999, CANCER RES, V59, P1433.
   Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349.
   Shadeo A, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1370.
   Simpson PT, 2004, J PATHOL, V202, P274, DOI 10.1002/path.1530.
   Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754.
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098.
   Souchelnytskyi S, 2002, J MAMMARY GLAND BIOL, V7, P359, DOI 10.1023/A:1024029930563.
   Stingl J, 1998, DIFFERENTIATION, V63, P201, DOI 10.1111/j.1432-0436.1998.00201.x.
   Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299.
   Tirkkonen M, 1998, GENE CHROMOSOME CANC, V21, P177, DOI 10.1002/(SICI)1098-2264(199803)21:3<177::AID-GCC1>3.0.CO;2-X.
   Tracy S, 2004, CANCER RES, V64, P7241, DOI 10.1158/0008-5472.CAN-04-1905.
   Vogel CL, 2005, CANCER RES, V65, P2044, DOI 10.1158/0008-5472.CAN-04-3943.
   Vogel CL, 2001, ONCOLOGY-BASEL, V61, P37, DOI 10.1159/000055400.
   Wouters L, 2003, BIOMETRICS, V59, P1131, DOI 10.1111/j.0006-341X.2003.00130.x.
   Zhao XJ, 2004, CANCER RES, V64, P3060, DOI 10.1158/0008-5472.CAN-03-3308.}},
Number-of-Cited-References = {{57}},
Times-Cited = {{1846}},
Usage-Count-Last-180-days = {{5}},
Usage-Count-Since-2013 = {{182}},
Journal-ISO = {{Cancer Cell}},
Doc-Delivery-Number = {{118PA}},
Unique-ID = {{ISI:000242953000009}},
OA = {{Green Accepted, Bronze}},
DA = {{2019-05-03}},
}

@article{ ISI:A1987F534400026,
Author = {SLAMON, DJ and CLARK, GM and WONG, SG and LEVIN, WJ and ULLRICH, A and
   MCGUIRE, WL},
Title = {{HUMAN-BREAST CANCER - CORRELATION OF RELAPSE AND SURVIVAL WITH
   AMPLIFICATION OF THE HER-2 NEU ONCOGENE}},
Journal = {{SCIENCE}},
Year = {{1987}},
Volume = {{235}},
Number = {{4785}},
Pages = {{177-182}},
Month = {{JAN 9}},
Publisher = {{AMER ASSOC ADVANCEMENT SCIENCE}},
Address = {{1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{SLAMON, DJ (Reprint Author), UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90024 USA.
   UNIV CALIF LOS ANGELES, SCH MED, JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA 90024 USA.
   UNIV TEXAS, HLTH SCI CTR, DEPT MED, DIV ONCOL, SAN ANTONIO, TX 78284 USA.
   GENENTECH INC, DEPT MOLEC BIOL, SAN FRANCISCO, CA 94080 USA.}},
DOI = {{10.1126/science.3798106}},
ISSN = {{0036-8075}},
EISSN = {{1095-9203}},
Research-Areas = {{Science \& Technology - Other Topics}},
Web-of-Science-Categories  = {{Multidisciplinary Sciences}},
Funding-Acknowledgement = {{NCI NIH HHS {[}CA 36827, CA 30195]}},
Cited-References = {{BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8.
   BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505.
   BRESLOW NE, 1975, INT STAT REV, V43, P45, DOI 10.2307/1402659.
   BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137.
   CAMPISI J, 1983, CELL, V33, P357.
   CLARK GM, 1983, NEW ENGL J MED, V309, P1343, DOI 10.1056/NEJM198312013092240.
   COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974.
   COX DR, 1972, J R STAT SOC B, V34, P187.
   CROCE CM, 1985, SCI AM, V252, P54, DOI 10.1038/scientificamerican0385-54.
   DEZIKES GJ, BIOCH BIOPHYS RES CO.
   DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883.
   DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0.
   ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969.
   ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834.
   FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955.
   GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0.
   HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0.
   HOROWITZ P, 1975, SCIENCE, V189, P795, DOI 10.1126/science.189.4205.795.
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868.
   KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089.
   KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1.
   LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0.
   MANIATIS T, 1982, MOL CLONING LABORATO, P282.
   MCGUIRE WL, 1978, SEMIN ONCOL, V5, P428.
   MEERAKKAN D, 1984, CYTOGENET CELL GENET, V37, P71.
   MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0.
   RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0.
   SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0.
   SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090.
   SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0.
   SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0.
   SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802.
   SEEGER RC, UNPUB.
   SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497.
   SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7.
   SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0.
   SILVERBERG E, 1986, CA-CANCER J CLIN, V36, P9.
   SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699.
   SLAMON DJ, 1984, P NATL ACAD SCI-BIOL, V81, P7141, DOI 10.1073/pnas.81.22.7141.
   ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0.
   VARMUS HE, 1984, ANNU REV GENET, V18, P553.
   WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0.
   WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659.
   YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898.}},
Number-of-Cited-References = {{44}},
Times-Cited = {{8550}},
Usage-Count-Last-180-days = {{49}},
Usage-Count-Since-2013 = {{625}},
Journal-ISO = {{Science}},
Doc-Delivery-Number = {{F5344}},
Unique-ID = {{ISI:A1987F534400026}},
DA = {{2019-05-03}},
}

@article{ ISI:000221496700005,
Author = {Lynch, TJ and Bell, DW and Sordella, R and Gurubhagavatula, S and
   Okimoto, RA and Brannigan, BW and Harris, PL and Haserlat, SM and Supko,
   JG and Haluska, FG and Louis, DN and Christiani, DC and Settleman, J and
   Haber, DA},
Title = {{Activating mutations in the epidermal growth factor receptor underlying
   responsiveness of non-small-cell lung cancer to gefitinib}},
Journal = {{NEW ENGLAND JOURNAL OF MEDICINE}},
Year = {{2004}},
Volume = {{350}},
Number = {{21}},
Pages = {{2129-2139}},
Month = {{MAY 20}},
Abstract = {{BACKGROUND:
   Most patients with non-small-cell lung cancer have no response to the
   tyrosine kinase inhibitor gefitinib, which targets the epidermal growth
   factor receptor (EGFR). However, about 10 percent of patients have a
   rapid and often dramatic clinical response. The molecular mechanisms
   underlying sensitivity to gefitinib are unknown.
   METHODS:
   We searched for mutations in the EGFR gene in primary tumors from
   patients with non-small-cell lung cancer who had a response to
   gefitinib, those who did not have a response, and those who had not been
   exposed to gefitinib. The functional consequences of identified
   mutations were evaluated after the mutant proteins were expressed in
   cultured cells.
   RESULTS:
   Somatic mutations were identified in the tyrosine kinase domain of the
   EGFR gene in eight of nine patients with gefitinib-responsive lung
   cancer, as compared with none of the seven patients with no response
   (P<0.001). Mutations were either small, in-frame deletions or amino acid
   substitutions clustered around the ATP-binding pocket of the tyrosine
   kinase domain. Similar mutations were detected in tumors from 2 of 25
   patients with primary non-small-cell lung cancer who had not been
   exposed to gefitinib (8 percent). All mutations were heterozygous, and
   identical mutations were observed in multiple patients, suggesting an
   additive specific gain of function. In vitro, EGFR mutants demonstrated
   enhanced tyrosine kinase activity in response to epidermal growth factor
   and increased sensitivity to inhibition by gefitinib.
   CONCLUSIONS:
   A subgroup of patients with non-small-cell lung cancer have specific
   mutations in the EGFR gene, which correlate with clinical responsiveness
   to the tyrosine kinase inhibitor gefitinib. These mutations lead to
   increased growth factor signaling and confer susceptibility to the
   inhibitor. Screening for such mutations in lung cancers may identify
   patients who will have a response to gefitinib.}},
Publisher = {{MASSACHUSETTS MEDICAL SOC/NEJM}},
Address = {{WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Lynch, TJ (Reprint Author), Massachusetts Gen Hosp, Ctr Canc, Bldg 149,13th St, Charlestown, MA 02129 USA.
   Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
   Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
   Harvard Univ, Sch Med, Boston, MA USA.
   Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.}},
DOI = {{10.1056/NEJMoa040938}},
ISSN = {{0028-4793}},
Keywords-Plus = {{TYROSINE KINASE INHIBITOR; PHASE-II TRIAL; EGF RECEPTOR; SOLID TUMORS;
   ZD1839; COMBINATION; PHENOTYPE; LEUKEMIA; EFFICACY; IRESSA}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Funding-Acknowledgement = {{NCI NIH HHS {[}R01 CA 092824, P50 CA 090578, P30 CA0516]; PHS HHS {[}P01
   95281]}},
Cited-References = {{Albanell J, 2002, J CLIN ONCOL, V20, P110, DOI 10.1200/JCO.20.1.110.
   Arteaga CL, 2003, EXP CELL RES, V284, P122, DOI 10.1016/S0014-4827(02)00104-0.
   Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596.
   Baselga J, 2002, J CLIN ONCOL, V20, P4292, DOI 10.1200/JCO.2002.03.100.
   Cohen MH, 2004, CLIN CANCER RES, V10, P1212, DOI 10.1158/1078-0432.CCR-03-0564.
   DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902.
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766.
   Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401.
   Fitch KR, 2003, GENE DEV, V17, P214, DOI 10.1101/gad.1023703.
   Frederick L, 2000, CANCER RES, V60, P1383.
   Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038.
   Giaccone G, 2004, J CLIN ONCOL, V22, P777, DOI 10.1200/JCO.2004.08.001.
   Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190.
   Herbst RS, 2004, J CLIN ONCOL, V22, P785, DOI 10.1200/JCO.2004.07.215.
   Herbst RS, 2002, J CLIN ONCOL, V20, P3815, DOI 10.1200/JCO.2002.03.038.
   Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8.
   Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149.
   Li B, 2003, CANCER RES, V63, P7443.
   LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399.
   Nielsen UB, 2003, P NATL ACAD SCI USA, V100, P9330, DOI 10.1073/pnas.1633513100.
   PAEZ JG, 2004, SCIENCE.
   Pegram M D, 2000, Cancer Treat Res, V103, P57.
   RANSON M, 2002, J CLIN ONCOL, V20, P2240, DOI DOI 10.1200/JCO.2002.10.112.
   Rich JN, 2004, J CLIN ONCOL, V22, P133, DOI 10.1200/JCO.2004.08.110.
   Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954.
   Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200.
   Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205.
   THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084.
   Wakeling AE, 2002, CANCER RES, V62, P5749.}},
Number-of-Cited-References = {{29}},
Times-Cited = {{7678}},
Usage-Count-Last-180-days = {{99}},
Usage-Count-Since-2013 = {{856}},
Journal-ISO = {{N. Engl. J. Med.}},
Doc-Delivery-Number = {{821XM}},
Unique-ID = {{ISI:000221496700005}},
OA = {{Green Published}},
DA = {{2019-05-03}},
}

@article{ ISI:000083121200061,
Author = {Golub, TR and Slonim, DK and Tamayo, P and Huard, C and Gaasenbeek, M
   and Mesirov, JP and Coller, H and Loh, ML and Downing, JR and Caligiuri,
   MA and Bloomfield, CD and Lander, ES},
Title = {{Molecular classification of cancer: Class discovery and class prediction
   by gene expression monitoring}},
Journal = {{SCIENCE}},
Year = {{1999}},
Volume = {{286}},
Number = {{5439}},
Pages = {{531-537}},
Month = {{OCT 15}},
Abstract = {{Although cancer classification has improved over the past 30 years,
   there has been no general approach for identifying new cancer classes
   (class discovery) or for assigning tumors to known classes (class
   prediction). Here, a generic approach to cancer classification based on
   gene expression monitoring by DNA microarrays is described and applied
   to human acute Leukemias as a test case. A class discovery procedure
   automatically discovered the distinction between acute myeloid Leukemia
   (AML) and acute Lymphoblastic Leukemia (ALL) without previous knowledge
   of these classes. An automatically derived class predictor was able to
   determine the class of new leukemia cases. The results demonstrate the
   feasibility of cancer classification based solely on gene expression
   monitoring and suggest a general strategy for discovering and predicting
   cancer classes for other types of cancer, independent of previous
   biological knowledge.}},
Publisher = {{AMER ASSOC ADVANCEMENT SCIENCE}},
Address = {{1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Golub, TR (Reprint Author), MIT, Whitehead Inst, Ctr Genome Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   MIT, Whitehead Inst, Ctr Genome Res, Cambridge, MA 02139 USA.
   Dana Farber Canc Inst, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Boston, MA 02115 USA.
   St Jude Childrens Res Hosp, Memphis, TN 38105 USA.
   Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
   Ohio State Univ, Canc \& Leukemia Grp B, Columbus, OH 43210 USA.
   MIT, Dept Biol, Cambridge, MA 02142 USA.}},
DOI = {{10.1126/science.286.5439.531}},
ISSN = {{0036-8075}},
Keywords-Plus = {{ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; ALVEOLAR
   RHABDOMYOSARCOMA; SACCHAROMYCES-CEREVISIAE; BURKITT-LYMPHOMA;
   SURFACE-ANTIGENS; TRANSLOCATION; CELLS; MICROARRAY; FUSION}},
Research-Areas = {{Science \& Technology - Other Topics}},
Web-of-Science-Categories  = {{Multidisciplinary Sciences}},
ResearcherID-Numbers = {{Downing, James/N-8102-2018
   }},
ORCID-Numbers = {{Slonim, Donna/0000-0003-3357-437X}},
Cited-References = {{BALABANMALENBAUM G, 1977, SCIENCE, V198, P739, DOI 10.1126/science.71759.
   BENNETT JM, 1969, BLOOD-J HEMATOL, V33, P341.
   Bishop JF, 1999, MED J AUSTRALIA, V170, P39, DOI 10.5694/j.1326-5377.1999.tb126866.x.
   Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159.
   BUCCHERI V, 1993, BLOOD, V82, P853.
   Cole KA, 1999, NAT GENET, V21, P38, DOI 10.1038/4466.
   CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847.
   DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824.
   DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503.
   DeRisi J, 1996, NAT GENET, V14, P457.
   DINNDORF PA, 1992, MED PEDIATR ONCOL, V20, P192, DOI 10.1002/mpo.2950200303.
   DOUGLASS EC, 1987, CYTOGENET CELL GENET, V45, P148, DOI 10.1159/000132446.
   FARBER S, 1948, NEW ENGL J MED, V238, P787, DOI 10.1056/NEJM194806032382301.
   Forkner CE, 1938, LEUKEMIA ALLIED DISO.
   FREI E, 1961, BLOOD, V18, P431.
   GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917.
   GOLUB TR, UNPUB.
   GRAHAM RC, 1965, J HISTOCHEM CYTOCHEM, V13, P150, DOI 10.1177/13.2.150.
   Huang SY, 1997, BRIT J HAEMATOL, V96, P682, DOI 10.1046/j.1365-2141.1997.d01-2100.x.
   Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83.
   Khan J, 1999, ELECTROPHORESIS, V20, P223, DOI 10.1002/(SICI)1522-2683(19990201)20:2<223::AID-ELPS223>3.0.CO;2-A.
   Khan J, 1998, CANCER RES, V58, P5009.
   Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844.
   Konopleva M, 1999, BLOOD, V93, P1668.
   Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714.
   Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536.
   Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675.
   MASTER PS, 1989, BLUT, V59, P221, DOI 10.1007/BF00320851.
   McLean TW, 1996, BLOOD, V88, P4252.
   {*}MED RES COUNC, 1963, BRIT MED J, V1, P7.
   Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154.
   PESANDO JM, 1979, BLOOD, V54, P1240.
   Pui CH, 1998, NEW ENGL J MED, V339, P605, DOI 10.1056/NEJM199808273390907.
   QUAGLINO D, 1959, J PATHOL BACTERIOL, V78, P521, DOI 10.1002/path.1700780219.
   ROMANA SP, 1995, BLOOD, V86, P4263.
   ROPER M, 1983, BLOOD, V61, P830.
   ROSS W, 1984, CANCER RES, V44, P5857.
   ROWLEY JD, 1973, ANN GENET-PARIS, V16, P109.
   SALLAN SE, 1980, BLOOD, V55, P395.
   Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614.
   SCHLOSSMAN SF, 1976, P NATL ACAD SCI USA, V73, P1288, DOI 10.1073/pnas.73.4.1288.
   Shurtleff SA, 1995, LEUKEMIA, V9, P1985.
   Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273.
   STEPHENSON CF, 1992, HUM PATHOL, V23, P1270, DOI 10.1016/0046-8177(92)90295-E.
   STONE RM, 1993, HEMATOL ONCOL CLIN N, V7, P47.
   Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907.
   TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837.
   Triche T J, 1988, Prog Clin Biol Res, V271, P475.
   TSUKIMOTO I, 1976, NEW ENGL J MED, V294, P245, DOI 10.1056/NEJM197601292940503.
   TURCCAREL C, 1986, CANCER GENET CYTOGEN, V19, P361, DOI 10.1016/0165-4608(86)90069-5.
   Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359.
   Yang GP, 1999, NUCLEIC ACIDS RES, V27, P1517, DOI 10.1093/nar/27.6.1517.}},
Number-of-Cited-References = {{52}},
Times-Cited = {{7149}},
Usage-Count-Last-180-days = {{28}},
Usage-Count-Since-2013 = {{625}},
Journal-ISO = {{Science}},
Doc-Delivery-Number = {{245RD}},
Unique-ID = {{ISI:000083121200061}},
DA = {{2019-05-03}},
}
